Deciphering the neurotoxic effects of emerging pollutants: Bisphenols and phthalates as disruptors of brain function and mental health Authors: Claudia Angélica Garay-Canales, Yair Rodríguez-Santiago, Diana Lizeth Ruiz-Antonio, Karen E. Nava-Castro, María del Sol Ríos-Avila, César Antonio Zavala-López, Yareni Danae Chavez-Ramos, Laura Sánchez-García, Luis Enrique Jiménez-Hernández, Lenin Pavón, Jorge Morales-Montor Published: 2026 ABSTRACT Bisphenols and phthalates, ubiquitous plasticizers in everyday products, are endocrine-disrupting compounds (EDCs) that leach from matrices, contributing to widespread human exposure. These EDCs disrupt endocrine functions, affecting neurodevelopmental processes and increasing the risk of long-term adverse effects. This review examines the impact of bisphenol A (BPA) and phthalates on brain function and mental disorders. Exposure to these EDCs, particularly during critical developmental periods (perinatal and early childhood), induces changes in the neuroendocrine system, correlating with neurobehavioral disorders observed in puberty and later life. The alarming rise in global mental health disorders, especially among those under 18 (48.4% of reported cases), underscores the need to address environmental contributors like EDCs. While genetic and psychosocial factors are established contributors, emerging evidence highlights the role of EDCs in psychopathology. Further research and regulation of these ubiquitous compounds are essential to mitigate their impact on brain function and mental health. Introduction In recent decades, the global incidence of mental health disorders has increased at an alarming rate, becoming one of the leading causes of disability and disease burden worldwide, with the most vulnerable population being those under 18 years of age, accounting for almost 48.4% of reported cases. While the role of genetic predisposition and psychosocial stressors in mental illness is well established, emerging evidence highlights the importance of environmental exposure, particularly to endocrine-disrupting compounds (EDCs), as modifiable factors contributing to psychopathology.1 Plasticizers, such as bisphenol A (BPA), enhance material properties but can leach out due to UV radiation, temperature, or pH changes, leading to human exposure through ingestion, inhalation, dermal absorption, and intravenous contact. BPA and analogs, used in plastics and consumer products, modulate estrogen receptors (ERs) and estrogen synthesis, exert antiandrogenic effects, and also affect the aryl hydrocarbon receptor (AHR), and peroxisome proliferator-activated receptor gamma (PPAR-γ), causing oxidative stress, mitochondrial dysfunction, and endocrine disruption, affecting hormone synthesis, reproduction, and neurodevelopment with long-term adverse effects.2 Phthalates, a class of industrial chemicals used as plasticizers since the 1930s, are ubiquitous in consumer products, including toys, medical devices, food containers, and cosmetics, thereby enhancing flexibility and durability. Categorized into low-molecular-weight (LMW) and high-molecular-weight (HMW) groups, phthalates include benzyl butyl phthalate (BBP), diethyl phthalate (DEP), and di(2-ethylhexyl) phthalate (DEHP). These chemicals have been detected in beverages and prepared meals, indicating potential human exposure through ingestion.3 The association between plasticizer exposure and mental disorders may be attributed to lifestyle factors, such as processed food consumption and indoor exposure, as well as impaired detoxification pathways in individuals with mental disorders. Fetal exposure to plasticizers is also critical, as it can induce long-term neurobiological alterations, affecting synaptogenesis, myelination, and hormonal reprogramming. Exposure to EDCs during developmental windows can alter neurogenesis, synaptic plasticity, and cognitive function, leading to behavioral changes and mood disorders. Specific plasticizers, such as DEHP and BPA, have been shown to induce neuroinflammation, compromise blood-brain barrier integrity, and dysregulate neurotransmitter pathways, contributing to the pathophysiology of mental disorders.4 The mechanisms underlying plasticizer-induced alterations involve disruption of hormone-regulated neurological development, including receptor binding, oxidative stress, and neuroinflammation, as well as direct genetic alterations, particularly in the amygdala.5 These changes can impair brain plasticity and neurocognitive development, especially in infants. Despite evidence linking plasticizers to adverse health effects, regulatory actions remain limited, and the impacts of BPA and DEHP analogs are poorly understood, highlighting the need to reassess environmental contaminants in mental health research and policy, focusing on synergistic mechanisms, metabolic dimorphism, and neurodevelopmental implications.5,6 Against this backdrop, this narrative review examines the epidemiological trends, experimental models, biological mechanisms, and public health implications of early exposure to phthalates and bisphenols. We advocate for a paradigm shift toward environmental prevention in psychiatric risk assessment, recognizing that understanding these factors is crucial for elucidating disease etiology and for informing effective prevention strategies and intervention policies aimed at reducing exposure to neurotoxic substances during vulnerable developmental periods. A comprehensive literature search was conducted using PubMed’s advanced search option, combining terms such as “bisphenols” and “phthalates” with keywords including “neurodevelopment,” “language,” “sociability,” “neurobehavioral,” “memory,” “learning,” “depression,” “anxiety,” and “autism.” Metabolism of endocrine disruptors and human exposure EDCs are lipophilic compounds that undergo a two-phase metabolic process, involving hydrolysis into monoesters in the intestine, followed by conversion into sulfo- or glucuro-conjugates, facilitating distribution and elimination. BPA undergoes extensive metabolism, primarily via glucuronidation catalyzed by UDP-glucuronosyltransferases (UGTs) in the liver and extrahepatic tissues, leading to rapid urinary excretion in humans. Minor metabolic pathways include sulfation, hydroxylation, and oxidation, producing metabolites such as BPA sulfate and oxidative products, which are eliminated through urine, feces, and sweat.7 Physiologically based kinetic (PBK) models reveal significant differences in the distribution and toxicokinetic profiles of bisphenol analogs, including bisphenol S (BPS), BPM, and bisphenol AF (BPAF), which accumulate in specific organs. Enterohepatic circulation contributes to prolonged exposure, with vulnerable populations, such as toddlers and children, experiencing higher internal concentrations due to age-related factors, including lower UGT2B15 expression.8 Phthalates are rapidly metabolized in the human body, with a short biological half-life of approximately 12 h. Their metabolic fate and toxicity depend on side-chain length: short-branched phthalates (e.g., Dimethyl phthalate [DMP] and Diethyl phthalate [DEP]) are hydrolyzed and excreted in urine, while long-branched phthalates (e.g., DEHP) undergo complex transformations and are excreted in urine and feces as phase 2 conjugated compounds. DEHP is metabolized to mono(2-ethylhexyl) phthalate (MEHP) and other oxidative metabolites, which are detectable in serum and urine. Certain metabolites, such as MEHP, can cause reproductive dysfunction by altering endocrine activity.9 The efficiency of oxidative metabolism varies with age, with children excreting more oxidative DEHP metabolites than adults. Biomarkers such as mono(2 ethyl 5 carboxypentyl) phthalate (MECPP) (urine) and mono(2 carboxyhexyl) phthalate (MCMHP) (serum) are used to assess exposure, and excretion occurs through urine, feces, and sweat10 (Figure 1).Figure 1Metabolism of endocrine disruptors in humansEDC metabolism is necessary to produce metabolites and conjugated metabolites with higher polarity and water solubility, which increase excretion by the kidneys and gut. The liver is the main site of metabolism in the body; however, the kidneys, skin, and gastrointestinal tract also participate in EDC biotransformation. Phase I includes oxidation, reduction, and hydrolysis. The oxidation process is catalyzed by a class of enzymes collectively called cytochrome P450 (CYP-450), present in the smooth endoplasmic reticulum of the liver. Phase II, or synthetic reactions, represent the most important metabolic reactions that decrease the affinity of EDCs through glucuronic acid, sulfate, amino acid, and glutathione conjugation, as well as acetylation and methylation. Created in https://BioRender.com. Metabolism of endocrine disruptors in humans EDC metabolism is necessary to produce metabolites and conjugated metabolites with higher polarity and water solubility, which increase excretion by the kidneys and gut. The liver is the main site of metabolism in the body; however, the kidneys, skin, and gastrointestinal tract also participate in EDC biotransformation. Phase I includes oxidation, reduction, and hydrolysis. The oxidation process is catalyzed by a class of enzymes collectively called cytochrome P450 (CYP-450), present in the smooth endoplasmic reticulum of the liver. Phase II, or synthetic reactions, represent the most important metabolic reactions that decrease the affinity of EDCs through glucuronic acid, sulfate, amino acid, and glutathione conjugation, as well as acetylation and methylation. Created in https://BioRender.com. Human biomonitoring studies showed in Table 1 reveal widespread exposure to bisphenols and phthalates, with detectable levels found in serum, urine, and feces across all age groups. High concentrations of BPA, BPS, and phthalate metabolites such as MEHP and mono-n-butyl phthalate (MnBP) are present, with notable differences in levels between age groups and sexes. For example, BPA levels are highest in neonates and infants (up to 66 ng/mL), while sex-related differences are seen in infants and older adults. These findings highlight the pervasive nature of exposure, affecting individuals of all ages, and underscore the need for urgent action to mitigate associated risks.15Table 1Bisphenols, phthalates, and metabolite levels in human matricesType of compoundChemicalMatrixPopulationConcentrationRegionReferencePrenatal stage (fetal development)BisphenolsBPAurinegestational period1.30–1.46 ng/mLDenmarkBeck et al.11BPAurine12–32 weeks of pregnancyGM 2.3 mg/LSpainCasas et al.12PhthalatesMEPUrinegestational period81–98 ng/mLUSAHoffman et al.13MBP10–11 ng/mLMiBP8–10 ng/mLMBzP5–6 ng/mLMEHP1.7–2.4 ng/mLMnBPUrinethird trimester of pregnancy37.6 ng/mLUSAFactor-Litvak et al.14MBzP13.4 ng/mLMEHHP22.3 ng/mLNeonates and infants (0–2 years)BisphenolsBPAurine, plasmanewborn15–66 ng/mLTurkeyCelik et al.15BPF1.0–5.5 ng/mLBPAUrine1–6 months of age2.23–3.22 μg/LChinaZhao et al.16BPSUrinenewborn0.09 ± 0.2 ng/mLItalyBellisario et al.17BPA0.13 ± 0.3 ng/mLBPAurinenewborn1.18–1.40 ng/mLDenmarkBeck et al.11PhthalatesDEHPurine♀1.0 nmol/LUSAStroustrup et al.18♂1.0 nmol/LMBP♀1.0 nmol/L♂1.25 nmol/LMBzP♀1.01 nmol/L♂1.13 nmol/LMiBP♀0.79 nmol/L♂11.5 nmol/LMEP♀0.6 nmol/L♂1.79 nmol/LMCPP♀1.77 nmol/L♂3.4 nmol/LEarly childhood (2–6 years)BisphenolsBPAurine3–5 years0.78 mg/g creatinineRepublic of KoreaChoi et al.19BPAurine2–3 years old1.93 mg/g creatinineTaiwanWang et al.204–6 years old6.16 mg/g creatinineBPAurine3–4 years of age1.0 ng/mLCanadaGrohs et al.21PhthalatesMnBPurine5 years old>80% (detection frequency)USAThistle et al.22MCPPMEPDEHPDiNP<10% (detection frequency)DINCH/DEHTP>97% (detection frequency)MBzPurine5 years1.7 ng/mLUSAWerder et al.23MCPP0.8 ng/mLMEP2.4 ng/mLMiBP2.5 ng/mLMnBP2.7 ng/mLMiddle childhood (6–11 years)BisphenolsBPAurine, blood6–11 years3.8–4.6 μg/gEuropeFabbri et al.24BPAurine9–18 years1.6 μg/LChinaWang et al.25BPAurine7–9 years0.62 mg/g creatinineRepublic of KoreaChoi et al.19BPAurine9–18 years1.6 μg/LChinaWang et al.25PhthalatesMiBPurine6–10 years27.3–30.5 μg/LGermanySchwedler et al.26MBzPurine, blood6–11 years old4.8–6.4 μg/gEuropeFabbri et al.24MECPPurine, blood–36.4–43.6 μg/gEuropeMEHHPurine, blood–19.9–24.4 μg/gEuropeAdolescence (12–18 years)BisphenolsBPAurine, blood13-year-old adolescents1,532 ng/dayPortugalMagalhães et al.27BPAurinemean age of 12.9 years1.3 mg/g creatinineChinaWang et al.25PhthalatesMMPurine13- to 15-year-old adolescents3.38 ng/mLNetherlandsBerghuis et al.28MEP22.03 ng/mLMiBP34.83 ng/mLMnBP24.41 ng/mLMEHP1.57 ng/mLMEHHP9.08 ng/mLAdulthood (19–59 years)BisphenolsBPAurinestudents 18–23 years old2.8 ng/mLSpainAdoamnei et al.29BPAurinewomen >50 years old6.6 ng/mLMexicoBarajas et al.30BPAplasma (infertile women)♀ between 20 and 40 years old4.66 ng/mLIndiaPednekar et al.31plasma (fertile women)2.64 ng/mLBPFurine♂ between 21 and 28 years0.10 mg/LChinaWang et al.32PhthalatesMEPurine20–45 years old33.1 ng/mLUSAFruh et al.33MBP11.2 ng/mLMBzP2.9 ng/mLMEHPurine (fertile and infertile men)♂ 32–36 years old4.9 ng/mLUSAMendiola et al.34Older adults (60 years)BisphenolsBPAurine♀ 65 years43.42–49.87 mg/g creatinineTaiwanChen et al.35♂ 65 years30.5 mg/g creatinineBPFUrine♀ 65 years38.52 mg/g creatinine♂ 65 years30.84 mg/g creatinineBPASerum60–70 years6.0 ng/mLChinaDuan et al.36BPB2.0 ng/mLBPC0.5 ng/mLBPE0.6 ng/mLBPF0.6 ng/mLBPAP0.1 ng/mLBPS1.44 ng/mLBPZ0.88 ng/mLBPP0.22 ng/mLPhthalatesMBPUrine60 years or over42.59 mg/g creatinineChinaCheng et al.37Different life stagesBisphenolsBPAurinemothers and children2.0 mg/g creatinineSpainCutanda et al.38BPSurinemothers and children126 ng/L creatinineChinaJialin et al.39PhthalatesMBPurineinfants and adults20–100 μg/LUSAWang et al.40 Table 1Bisphenols, phthalates, and metabolite levels in human matricesType of compoundChemicalMatrixPopulationConcentrationRegionReferencePrenatal stage (fetal development)BisphenolsBPAurinegestational period1.30–1.46 ng/mLDenmarkBeck et al.11BPAurine12–32 weeks of pregnancyGM 2.3 mg/LSpainCasas et al.12PhthalatesMEPUrinegestational period81–98 ng/mLUSAHoffman et al.13MBP10–11 ng/mLMiBP8–10 ng/mLMBzP5–6 ng/mLMEHP1.7–2.4 ng/mLMnBPUrinethird trimester of pregnancy37.6 ng/mLUSAFactor-Litvak et al.14MBzP13.4 ng/mLMEHHP22.3 ng/mLNeonates and infants (0–2 years)BisphenolsBPAurine, plasmanewborn15–66 ng/mLTurkeyCelik et al.15BPF1.0–5.5 ng/mLBPAUrine1–6 months of age2.23–3.22 μg/LChinaZhao et al.16BPSUrinenewborn0.09 ± 0.2 ng/mLItalyBellisario et al.17BPA0.13 ± 0.3 ng/mLBPAurinenewborn1.18–1.40 ng/mLDenmarkBeck et al.11PhthalatesDEHPurine♀1.0 nmol/LUSAStroustrup et al.18♂1.0 nmol/LMBP♀1.0 nmol/L♂1.25 nmol/LMBzP♀1.01 nmol/L♂1.13 nmol/LMiBP♀0.79 nmol/L♂11.5 nmol/LMEP♀0.6 nmol/L♂1.79 nmol/LMCPP♀1.77 nmol/L♂3.4 nmol/LEarly childhood (2–6 years)BisphenolsBPAurine3–5 years0.78 mg/g creatinineRepublic of KoreaChoi et al.19BPAurine2–3 years old1.93 mg/g creatinineTaiwanWang et al.204–6 years old6.16 mg/g creatinineBPAurine3–4 years of age1.0 ng/mLCanadaGrohs et al.21PhthalatesMnBPurine5 years old>80% (detection frequency)USAThistle et al.22MCPPMEPDEHPDiNP<10% (detection frequency)DINCH/DEHTP>97% (detection frequency)MBzPurine5 years1.7 ng/mLUSAWerder et al.23MCPP0.8 ng/mLMEP2.4 ng/mLMiBP2.5 ng/mLMnBP2.7 ng/mLMiddle childhood (6–11 years)BisphenolsBPAurine, blood6–11 years3.8–4.6 μg/gEuropeFabbri et al.24BPAurine9–18 years1.6 μg/LChinaWang et al.25BPAurine7–9 years0.62 mg/g creatinineRepublic of KoreaChoi et al.19BPAurine9–18 years1.6 μg/LChinaWang et al.25PhthalatesMiBPurine6–10 years27.3–30.5 μg/LGermanySchwedler et al.26MBzPurine, blood6–11 years old4.8–6.4 μg/gEuropeFabbri et al.24MECPPurine, blood–36.4–43.6 μg/gEuropeMEHHPurine, blood–19.9–24.4 μg/gEuropeAdolescence (12–18 years)BisphenolsBPAurine, blood13-year-old adolescents1,532 ng/dayPortugalMagalhães et al.27BPAurinemean age of 12.9 years1.3 mg/g creatinineChinaWang et al.25PhthalatesMMPurine13- to 15-year-old adolescents3.38 ng/mLNetherlandsBerghuis et al.28MEP22.03 ng/mLMiBP34.83 ng/mLMnBP24.41 ng/mLMEHP1.57 ng/mLMEHHP9.08 ng/mLAdulthood (19–59 years)BisphenolsBPAurinestudents 18–23 years old2.8 ng/mLSpainAdoamnei et al.29BPAurinewomen >50 years old6.6 ng/mLMexicoBarajas et al.30BPAplasma (infertile women)♀ between 20 and 40 years old4.66 ng/mLIndiaPednekar et al.31plasma (fertile women)2.64 ng/mLBPFurine♂ between 21 and 28 years0.10 mg/LChinaWang et al.32PhthalatesMEPurine20–45 years old33.1 ng/mLUSAFruh et al.33MBP11.2 ng/mLMBzP2.9 ng/mLMEHPurine (fertile and infertile men)♂ 32–36 years old4.9 ng/mLUSAMendiola et al.34Older adults (60 years)BisphenolsBPAurine♀ 65 years43.42–49.87 mg/g creatinineTaiwanChen et al.35♂ 65 years30.5 mg/g creatinineBPFUrine♀ 65 years38.52 mg/g creatinine♂ 65 years30.84 mg/g creatinineBPASerum60–70 years6.0 ng/mLChinaDuan et al.36BPB2.0 ng/mLBPC0.5 ng/mLBPE0.6 ng/mLBPF0.6 ng/mLBPAP0.1 ng/mLBPS1.44 ng/mLBPZ0.88 ng/mLBPP0.22 ng/mLPhthalatesMBPUrine60 years or over42.59 mg/g creatinineChinaCheng et al.37Different life stagesBisphenolsBPAurinemothers and children2.0 mg/g creatinineSpainCutanda et al.38BPSurinemothers and children126 ng/L creatinineChinaJialin et al.39PhthalatesMBPurineinfants and adults20–100 μg/LUSAWang et al.40 Bisphenols, phthalates, and metabolite levels in human matrices Neurobehavioral disorders: Functions of the brain modified by EDCs As previously mentioned, continuous exposure to emerging contaminants, such as plasticizers, can modify the structures of the nervous system regardless of age. This led us to ask whether a modification at the structural level could cause direct consequences on the development of cognitive abilities regardless of age or type of exposure. Neurobehavioral development arises from the synergistic interaction between intrinsic (genetic and epigenetic) and extrinsic (socio-environmental and experiential) factors, which operate through bidirectional feedback mechanisms and provide the ability to make sense of the stimuli that continuously cross our path.41 This development does not occur spontaneously but rather gradually, making the first 3 years of human life crucial for the development of motor circuits, including speech and motor skills.42 From this age, neurobehavioral development becomes a little more relaxed while strengthening language skills, thinking, and intra- and interpersonal relationships. As this period is so sensitive, any alteration, whether physical or mental, could generate consequences in the development of living beings, including social interaction, language features, and motor problems.43 To evaluate neurodevelopment, several indices can be used, such as the Bayley Scales of Infant and Toddler Development (BSID-II), which assesses and evaluates the mental, psychomotor, and behavioral development of children between 1 and 42 months of age.44 With chronic exposure to various types of plasticizers, it is important to focus on experiments that relate alterations in the neurobehavioral development of living beings to the concentration of plasticizers to which they may be exposed. Language development The definition of language has been built over the years. Some have defined it as the simple construction of sentences,45 others have considered it as a communicative system depending on cultural perspective,46 while others have emphasized an intrinsic relationship between its degree of complexity and the individual’s level of thought and understanding.47 The truth is that, regardless of its definition, language has the capacity to delimit the world in which we live through the conceptualization of the space, objects, and events in which we find ourselves immersed.48 If language development becomes deficient, individuals will have difficulty understanding others and the environment in which they reside.46 Because of these considerations, studies have been conducted that delve into language development with exposure to emerging contaminants such as phthalates and bisphenols. Psychological tests such as the MacArthur-Bates Communicative Development Inventories (MB-CDI) and Bayley Scales of Infant Development, as well as analytical methods, have been used to measure the concentration of parent compounds and metabolites in the urine of participants at different timescales. Particularly noteworthy in the literature are the perinatal studies in humans in which high concentrations of parent compounds and metabolites in the urine of the mother during gestation and of the children in the first months of life are related to low levels of language development.49 In general, the phthalate associated with low scores on language development tests is monobenzyl phthalate (MBzP), a metabolite of BBP. In contrast, high concentrations of mono-carboxy nonyl phthalate (MCNP) and mono-carboxy-isooctyl phthalate (MCOP) in urine have been associated with high levels of vocabulary and complexity. However, when these two metabolites are present at concentrations similar to those of monomethyl phthalate (MMP) and mono(3-carboxypropyl) phthalate (MCPP), language levels tend to decrease,50 which suggests synergistic mechanisms that develop within the body, of which much remains to be scrutinized. Regarding bisphenols, prenatal exposure has been linked to global alterations in cognitive development. Studies show that high concentrations of BPA in maternal urine correlate with lower scores in expressive vocabulary and verbal comprehension in children.51 These language deficiencies have been associated with the fact that prenatal exposure to BPA can alter the development of the prefrontal cortex through damage to stages of neurogenesis or synaptic pruning, in addition to altering the levels and secretion of neurotransmitters such as dopamine and serotonin in frontal and limbic regions, so that support functions in language development (motivation, attention, and inhibitory control) will be similarly compromised.52 Studies such as Danielson et al. and Lucaccioni et al. have described dimorphic differences. Boys tend to have lower scores on language tests than girls, indicating a lower degree of complexity, vocabulary, comprehension, and mastery.53,54 Also, studies with BPA show similar results between sexes; however, the majority still indicate a greater impact on men. Memory and learning Learning is a capacity that all animals possess dimensionally and that allows them to develop adaptive behaviors. In psychology, learning refers to the processes by which behavior is modified over time and in relation to the environment.55 Learning goes hand in hand with memory as interdependent mechanisms. Memory can be defined as the neurocognitive process that encodes, records, and subsequently retrieves information from the outside.56 All of these processes are carried out through neuroanatomical structures such as the hippocampus, the prefrontal cortex, and the amygdala, which can be affected by plasticizers. The synergistic interaction of both implies a transformation in behavioral responses resulting from the internalization of experiences, their encoding, retention, and reactivation according to the needs of the subject. If memory is altered or fails, it can cause learning difficulties. Phthalates such as DEHP and its metabolites are produced and are associated with decreased memory and learning abilities.57 A prenatal study in mice showed that at higher DEHP concentrations, the time spent searching for the hidden platform in the Morris water maze test increased, while the time spent in the target quadrant during a test trial decreased, but only in males. Analysis of the male hippocampus showed a decrease in the levels of N-methyl-D-aspartic acid (NMDA) receptor subunits NR1 and NR2B, components of the NMDA receptor that are involved in the modulation of functions such as learning, memory, and pain perception.58 In adult mouse models and at low doses of DEHP, a decrease in learning, memory, and social novelty preference was observed regardless of the sex of the mouse and was linked to an increase in reactive oxygen species (ROS)/reactive nitrogen species (RNS) and corticosteroids, and decreased activity of glutamine synthetase and neurotransmission.59 If doses are increased, learning and memory capacities are drastically modified, having a strong correlation with a deterioration in neural function due to the suppression of Kv-induced excitability of the cornu ammonis 3 (CA3)-cornu ammonis 1 (CA1) neural circuit.60 Similar results were obtained in a perinatal mouse model of BPA exposure, which directly impacts their neuroplasticity61 Regarding learning, several studies relate blood-brain barrier disruption; increased TNF-α and NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3)/caspase-1/IL-1β inflammasome pathway; loss of dendritic spine density; and postsynaptic markers with decreased spatial exploration abilities, increased latencies across days to find the platform, inability to show a preference for a new object, and increased latency to find the platform quadrant. It is worth mentioning that, as in language, males show worse impairments to phthalate exposure than females. According to studies by Ducroq et al. and Ren et al. in 2023, exposed males were no longer able to discriminate between more recently seen objects and older ones. This indicates an increased susceptibility of males to learning and memory problems after exposure to phthalates, regardless of their age.62,63 In contrast to the studies conducted with phthalates, experiments using BPA have also reported low levels of working memory development64 and decreased associative learning abilities,65,66,67 but these results have been independent of sex. Human studies have reported decreased levels of working memory development associated with high levels of urinary BPA, indicating impairment in these skills, reinforcing the direct impact of plasticizers on synaptic plasticity mechanisms and cognitive ability.64 Likewise, decreased associative learning abilities have also been observed in mice, linked to a reduction in dopaminergic receptors (D2 and DAT).68,69 Social skills According to Goldstein, the development of social skills involves sequential learning processes, where simple skills (e.g., protocol greeting) serve as the basis for mastering complex behaviors (e.g., mediation in group crises).70 Social skills are thus neurocognitive processes that allow interpreting socioemotional signals, generating adaptive responses in interpersonal contexts, and regulating behaviors to maintain functional relationships. Therefore, these processes are learned and consider moral, legal, and social norms (explicit and tacit) within a given sociocultural context. According to the Spanish psychologist María Inés Monjas, knowing how to relate well with others is not innate and requires considering how we think about social situations, how we handle our emotions when interacting, what concrete actions we choose to perform, and how all of the above is shaped by practice and experience.71 Beings that are not entirely isolated interact with environmental pollution, which can damage living organisms and complicate the coexistence networks in which they find themselves. Studies associate prenatal human exposures to DEHP with problems in social skills, such as emotional reactivity, somatic complaints, social withdrawal, and behavioral problems.72 These associations are sustained throughout childhood. A study in children aged 2–14 years found that predominant levels of MEHP in mothers’ urine during gestation were associated with higher scores on internalizing and externalizing problems. Whereas, if the predominance was in DEHP metabolites, scores for delinquent behavior and externalizing problems increased significantly. When analyzing children’s urinary levels of MBzP, positive associations were found between higher levels of this metabolite and social problems.73 In contrast, neonates exposed to DEHP via the central venous catheter showed associations between higher DEHP levels and greater problem-solving and gross motor skills. On the other hand, dimorphic behavior has also been observed in social skills. For example, it has been reported that girls tend to develop better hand-eye coordination independently of the concentrations of phthalates in circulation compared to boys.74 Following this same line, Rolland and collaborators conducted a perinatal study with 151 children around 24 months of age in which they measured whether their attention and perception could vary according to the concentrations of phthalate metabolites measured in their mothers’ urine. The results showed that when girls were exposed to high concentrations of MBzP in the second and third trimesters of gestation, their fixation duration tended to decrease. However, if concentrations were higher only in the third trimester but not in the second trimester, the time spent looking at a novel face and eyes increased. For males, regardless of trimester, a higher concentration of MnBP tended to increase their reaction times and decrease their processing speed. These observations show that plasticizers not only have the ability to act on different areas of the brain and thus affect different abilities but also that their effects can be modified in a dimorphic manner.75 In addition, a study performed on 97 twins at 2 years of age prenatally exposed to DEHP showed that, although they were exposed to the same compounds for the same amount of time, the monochorionic diamniotic (MCDA) twins had greater neurodevelopmental differences compared to the dichorionic diamniotic (DCDA) twins. This could lead us to think that, regardless of age and type of exposure, plasticizers have different routes by which they can modify individual behaviors, routes that, unfortunately, have not yet been fully studied. Regarding bisphenols, high urinary BPA concentrations during the second trimester of pregnancy were found to be associated with low scores on the Bayley-III socioemotional subscale, primarily in boys. However, results obtained on the social communication questionnaire (K-SCQ) scale showed an increased likelihood of social communication difficulties, primarily in girls. These results reveal a tendency for dimorphic behavior depending on the scale evaluated, the study subjects, and age; therefore, this cannot be considered universal. These observations demonstrate that plasticizers not only can act on different areas of the brain and, consequently, affect various abilities, but their effect can also be modified dimorphically. Although several studies have identified a dimorphic tendency in the development of neurocognitive skills after subjects were exposed to plasticizers, there is still no consensus to support these differences. In general, it has been observed that exposure to plasticizers tends to be negatively associated with the development of memory, learning, language, and social skills in males compared to females. This tendency may be due to the mechanism by which plasticizers interact with the neuroendocrine system, altering hormonal signaling that is crucial for neurological development (Figure 2). Numerous studies have described behavioral effects caused by mechanisms such as neuroinflammation, alterations in the neuroendocrine system, and morphological changes in the nervous system caused by exposure to plasticizers such as phthalates and bisphenols, thus compromising the consolidation of social skills from the early stages of brain development.Figure 2Functions of the brain altered by plasticizersBBB, blood-brain barrier. ↓ decrease ↑ increase. Created in https://BioRender.com. Functions of the brain altered by plasticizers BBB, blood-brain barrier. ↓ decrease ↑ increase. Created in https://BioRender.com. Several questions remain unanswered regarding the impact of early-life exposure to plasticizers on neurodevelopmental alterations, including learning, memory, language, and social skills. Given that these behaviors can persist over time due to ongoing exposure or critical situations, it is plausible that these effects contribute to the development of mental disorders. To address this issue, the following section summarizes and critically discusses evidence linking exposure to EDCs, specifically bisphenols and phthalates, with neurobehavioral alterations and mental health outcomes, integrating findings from human and animal studies. Growing epidemiological evidence indicates that prenatal and early-life exposure to these plasticizers is associated with alterations in cognitive and behavioral domains, including memory, attention, emotional regulation, and social interaction.1 These functional changes may precede the development of complex disorders, such as depression, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). Human studies have primarily identified these associations through standardized behavioral assessments and diagnostic tools. Parallel experimental animal studies have demonstrated that exposure to bisphenols and phthalates during critical windows of brain development induces persistent, often sex-specific, alterations in learning, memory, affective-like behavior, and sociability, as assessed through validated paradigms (Figure 3). These findings converge with human association studies to elucidate the neurodevelopmental and neuropsychiatric risks associated with bisphenol and phthalate exposure.Figure 3Behavioral test employed in animal models to diagnose pathological disordersIn depression models, the forced swim test is used to measure behavioral despair, and the three-chamber social interaction test assesses social behavior. In autism models, the three-chamber social interaction test evaluates social deficits, while the ultrasonic vocalization test measures communication impairments. For anxiety, the open field test is used to assess exploratory behavior, and grooming behavior is analyzed as an indicator of hyperactivity. Finally, in ADHD models, grooming is evaluated as a marker of anxiety, and the 5-choice serial reaction time task is used to assess impulsivity. Created in https://BioRender.com. Behavioral test employed in animal models to diagnose pathological disorders In depression models, the forced swim test is used to measure behavioral despair, and the three-chamber social interaction test assesses social behavior. In autism models, the three-chamber social interaction test evaluates social deficits, while the ultrasonic vocalization test measures communication impairments. For anxiety, the open field test is used to assess exploratory behavior, and grooming behavior is analyzed as an indicator of hyperactivity. Finally, in ADHD models, grooming is evaluated as a marker of anxiety, and the 5-choice serial reaction time task is used to assess impulsivity. Created in https://BioRender.com. Bisphenols and phthalates: Their association with mental disorders Anxiety and depression Anxiety is a natural emotion marked by worry, physical tension, and a sense that something bad might happen. While occasional anxiety is normal, research shows it can also impact the body in measurable ways, raising blood pressure, lowering pain tolerance, increasing stress, and weakening the immune system.76 However, when these feelings become excessive or persistent—far beyond everyday nervousness—they may develop into an anxiety disorder. Such disorders can interfere with focus, learning, decision-making, and performance at school or work.77 Anxiety commonly overlaps with depression, a mood disorder, a state of prolonged sadness or hopelessness that disrupts daily life. Major depression has clinical manifestations, such as shifts in sleep or appetite, low energy, trouble concentrating, and social withdrawal.76 Both conditions are shaped by cultural and social factors, and emerging studies suggest that exposure to EDCs might also play a role. Interestingly, anxiety disorders often emerge first and frequently coexist with depression, making their symptoms difficult to untangle.78 Exposure to BPA and its analogs has been shown to have distinct effects on anxiety and depression, with outcomes influenced by the timing and target population of exposure (Table 2). In the CCCEH cohort, Roen and colleagues found that prenatal BPA exposure was associated with increased anxious/depressed symptoms in boys at ages 7–9, suggesting greater male vulnerability. However, this pattern reversed for postnatal exposure measured in spot urine at ages 3 or 5; higher postnatal BPA was linked with greater anxiety/depression symptoms in girls and lower symptoms in boys.85 Sex-specific findings are not consistent across cohorts. For example, the HOME study associated prenatal BPA with anxiety and depression in girls, while childhood BPA concentrations showed no relationship with these outcomes.86Table 2Bisphenols and phthalates are associated with mental disordersStudied population cohort/sexTestAge at outcomeSample timing and typePlasticizer concentration (mean, median, or geometric mean)Main outcomeSex differencesReferenceAnxiety/depressionCCCEH cohort USA277 children: 129 ♂/148 ♀CBCL3 yearsmaternal spot urine:third trimester of gestationMBzP 19 ng/mLanxious/depressed symptomsMBzP: ↑ ♂/N.A ♀Whyatt et al.79SFF cohort USA153 children: 77 ♂/76 ♀CBCL6–10 yearsmaternal spot urine:27 weeks of gestationMBzP ♂ 6.43 and ♀ 6.76 ng/mLΣDEHPanxious/depressed symptomsMBzP: N.A ♂/↓ ♀ΣDEHP: N.A ♂/↓ ♀Kobrosly et al.80TMICS cohort, Taiwan.78 children: 37 ♂/41 ♀CBCL8,11, and 14 yearsmaternal spot urine:third trimester of gestationΣDEHP 4.56 μg/kg_bw/dayanxious/depressed symptomsΣDEHP 8 years: N.AΣDEHP 11 years: N.A ♂/↑ ♀ΣDEHP 14 years: N.A ♂/↑ ♀Chen et al.81Study group, Taiwan.491 children: 245 ♂/246 ♀CBCL3 yearsmaternal spot urine: second trimester of gestationMnBP ♂ 10.489 and ♀ 10.604 μg/ganxious/depressed symptomsassociated with anxious/depressed symptomsHuang et al.82TMICS cohort, Taiwan.408 children: 222 ♂/186 ♀CBCL and DSM-V3 yearsmaternal spot urine: third trimester of gestationMnBP ♂ 22.82 and ♀ 22.83 μg/gMiBP ♂ 11.07 and ♀ 12.94 μg/gdepression problemsMnBP and MiBP: associated with depression problemsTsai et al.83APrON cohort, Canada.351 childrenCBCL and BASC-23–4 yearsmaternal spot urine: second trimester of gestationMBzP 8.13 μg/LMECPP 14.81 μg/LMEOHP 8.45 μg/LMBP 16.66 μg/LMiBP 9.71 μg/LMEHP 3.31 μg/LMEP 17.29 μg/Lanxious/depressed symptomsMEHP, MECPP, and MEP: associated with anxious/depressed symptomsMBzP, MECPP, MEEOHP, MBP, and MiBP: associated with anxietyMiBP: associated with depressionEngland-Mason et al.84CCCEH cohort, USA.250 children: 115 ♂/135 ♀CBCL7–9 yearsmaternal spot urine: third trimester of gestationBPA ♂ 3.2 and♀ 3.4 μg/Lanxious/depressed symptomsBPA: ↑ ♂/N.A ♀Roen et al.85children spot urine: 3 or 5 yearsBPA ♂ 5.4 and ♀ 10.4 μg/LBPA: ↓ ♂/↑ ♀HOME cohort, USA.240 children: 112 ♂/128 ♀BASC-23 yearsmaternal spot urine: 16 and 26 weeks of gestation; <24 h post-deliveryBPA 2.2 μg/ganxiety and depressionBPA: ↑ ♀/N.A ♂Braun et al.86children spot urine: 1, 2, and 3 yearsBPA 14 μg/gBPA: N.AAutism spectrum disorderMIREC cohort, Canada.556 children: 268 ♂/288 ♀SRS-23–4 yearsmaternal spot urine: first trimester of gestationMBP ♂ 14.2 and ♀ 11.5 μg/LMCPP ♂ 1.06 and ♀ 0.90 μg/LASD-related behaviorsMBP and MCPP: ↑ ♂/N.A ♀Oulhote et al.87Study group, Turkey.51 autistic children50 control childrenDSM-IV6 yearsplasma:6 yearsBPA 2.15 and 1.12 ng/mLhigh levels of plasticizers in ASD patientsno differencesKondolot et al.88DEHP 0.198 and 0.172 ng/mLMEHP 0.068 and 0.088 ng/mLStudy group, USA.50 autistic children53 control childrenDSM-IV11 yearschildren spot urine: 11 yearsMEHP 20.18 and 15.80 ng/mLhigh levels of plasticizers in ASD patientsno differencesStein et al.895-oxo MEHP 5.31 and 5 ng/mL5-OH MEHP 10.84 and 10.66 ng/mL5-cx MEPP 433.89 and 341.06 ng/mLMIREC cohort, Canada.478 children: 235 ♂/243 ♀SRS-23–4 yearsmaternal spot urine: first trimester of gestationBPA 0.84 μg/LASD-related behaviorsBPA, MBP, and MCPP: ↑↑ ♂/↑ ♀MEP: ↓ ♂/↓ ♀Alampi et al.90MBP 12.7 μg/LMBzP 5.45 μg/LMCPP 0.89 μg/LMEHHP 9.55 μg/LMEHP 2.34 μg/LMEOHP 6.78 μg/LMEP 32.2 μg/LΣDEHP 18.8 μg/LEARLI cohort, USA.140 children: 77 ♂/63 ♀SRS3 yearsmaternal spot urine: first, second, and third trimester of gestationMCPP 2.10 ng/mLMiBP 9.35 ng/mLMBzP 6 ng/mLMBP 13.10 ng/mLMEP 26.95 ng/mLASD-related behaviorsN.APatti et al.91HOME cohort, USA.276 children: 123 ♂/153 ♀SRS4–8 yearsmaternal spot urine: 16 and 26 weeks of gestationMCPP 3.36 ng/mLMiBP 5 ng/mLMBzP 9.36 ng/mLMBP 23.40 ng/mLMEP 117.48 ng/mLASD-related behaviorsMCPP: ↑ ♂/N.A ♀MiBP, MBzP, MBP, and MEP: ↑↑ ♂/↑ ♀MABC cohort, China.3,209 children: 1,639 ♂/1,570 ♀CHAT-23 and CABS1.5, 3, 5, and 6 yearsmaternal spot urine: first, second, and third trimester of gestation1.5 years: MEP 6.72 μg/g, MEHHP 7.16 μg/g3 years: MMP 18.76 μg/g, MEHP 4.31 μg/g, MEOHP 8.75 μg/g5 years: MMP and MEHP6 years: MMPASD-related behaviorsassociated1.5 years: MEP and MEHHP3 years: MMP, MEHP, and MEOHP5 years: MMP and MEHP6 years: MMPGao et al.92Study group, Turkey.48 autistic children41 control childrenDSM-IV3–12 yearsserum samples: 3–12 yearsMEHP 0.47 and 0.29 μg/mLDEHP 2.70 and 1.62 μg/mLBPA 1.25 and 0.88 ng/mLhigh levels of plasticizers in ASD patientsMEHP, DEHP, and BPA: ↑ ASDKardas et al.93OCC cohort, Denmark.425 children: 223 ♂/202 ♀CBCL2 and 5 yearsmaternal spot urine: 28 weeks of gestationBPA 1.2 ng/mLASD-related behaviorsBPA 2 years:↑ ♂/↑↑ ♀BPA 5 years:N.AHansen et al.94Attention-deficit/hyperactivity disorderEDC cohort, South Korea.619 children: 325 ♂/294 ♀ARS- IV4,6, and 8 yearschildren spot urine:4, 6, and 8 years4 years:BPA ♂ 3.28 and ♀ 3.3 μg/g6 years:BPA ♂ 2.40 and ♀ 2,33 μg/gBPF ♂ 0.20 and ♀ 0.20 μg/gBPS ♂ 0.09 and ♀ 0.10 μg/g8 years:BPA ♂ 2.07 and ♀ 1.84 μg/gBPF ♂ 0.42 and ♀ 0.39 μg/gBPS ♂ 0.16 and ♀ 0.15 μg/gADHD-related behaviorsBPA 4 years: N.ABPA, BPF, and BPS 6 years:↑ ♂/↑↑ ♀BPA, BPF, and BPS 8 years: N.AKim et al.95CHARGE cohort, USA.225 autistic children236 control childrenABC-ADHD oriented2–5 yearschildren spot urine: 2–5 yearsMBzP 30.4 ng/mLMHPP 1.3 ng/mLMNBP 39.7 ng/mLADHD-related behaviorsMBzP ↑/N.AMHPP ↑/N.AMNBP ↑/N.AOh et al.96South Korea.78 ♂ ADHD children438 ♂ control childrenDSM-IVARS-IV6–15 yearschildren spot urine: 6–15 yearsMEHP 48.18 and 25.30 μg/gMEOP 43.99 and 20.53 μg/gMBP 65.96 and 50.86 μg/ghigh levels of plasticizers on ADHD patientsMEHP ↑ ADHDMEOP ↑ ADHDMBP ↑ ADHDPark et al.97MoBa cohort, Norway.295 ADHD children; 213 ♂/82 ♀551 control children: 273 ♂/278 ♀ICD-10not specifiedmaternal spot urine: 17 weeks of gestationΣDEHP 0.31 and 0.27 μmol/Lodds of ADHDΣDEHP: ↑ ♂/↑↑ ♀Engel et al.98NHANES, USA.460 children: 237 ♂/223 ♀DISC-IV8–15 yearschildren spot urine: 8–15 yearsBPA 3.67 μg/LADHD symptomsBPA: ↑↑ ♂/↑ ♀Tewar et al.99OCC cohort, Denmark.425 children: 223 ♂/202 ♀CBCL2 and 5 yearsmaternal spot urine: 28 weeks of gestationBPA 1.2 ng/mLADHD-related behaviorsBPA: N.AHansen et al.94Turkey.45 ADHD patients: 37 ♂/8 ♀30 control patients: 20 ♂/10 ♀DSM-V6–16 yearsserum samples: 6–16 yearsBPA 304 and 257.03 pg/mLhigh levels of plasticizers on ADHD patientsBPA: ↑ ADHDBaykal et al.100C-ABS cohort, China.1,783 childrenASQ3 and 4 yearsmaternal serum samples: first trimester of gestationBPA 0.23 ng/mLADHD-related behaviorsBPA: ↑ 3 years/N.A 4 yearsHuang et al.101MoBa cohort, Norway.260 ADHD children: 145 ♂/115 ♀549 control children: 275 ♂/274 ♀CBCL and DSM-IV3 yearsmaternal spot urine: 17 weeks of gestationMnBP 20 and 18.1 μg/Lodds of ADHDMnBP: ↑ ♂/N.A ♀Kamai et al.102↑Concentration associated with high symptoms/mental disorder; ↑↑ stronger associated with high symptoms compared to other sex; ↓ concentration associated with lower symptoms; N.A, no associated.CBCL, Child Behavior Checklist; BASC, Behavior Assessment System for Children; HDRS, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; SRS-2, Social Responsiveness Scale-II; ARS, ADHD Rating Scale IV; ICD-10, 10th revision of International Classification of Diseases; DSM, Diagnostic and Statistical Manual of Mental Disorders; CHAT-23, Checklist for Autism in Toddlers; CABS, Clancy Autism Behavior Scale; ASQ, Conners’ Abbreviated Symptom Questionnaire; DISC, Diagnostic Interview Schedule for Children. Table 2Bisphenols and phthalates are associated with mental disordersStudied population cohort/sexTestAge at outcomeSample timing and typePlasticizer concentration (mean, median, or geometric mean)Main outcomeSex differencesReferenceAnxiety/depressionCCCEH cohort USA277 children: 129 ♂/148 ♀CBCL3 yearsmaternal spot urine:third trimester of gestationMBzP 19 ng/mLanxious/depressed symptomsMBzP: ↑ ♂/N.A ♀Whyatt et al.79SFF cohort USA153 children: 77 ♂/76 ♀CBCL6–10 yearsmaternal spot urine:27 weeks of gestationMBzP ♂ 6.43 and ♀ 6.76 ng/mLΣDEHPanxious/depressed symptomsMBzP: N.A ♂/↓ ♀ΣDEHP: N.A ♂/↓ ♀Kobrosly et al.80TMICS cohort, Taiwan.78 children: 37 ♂/41 ♀CBCL8,11, and 14 yearsmaternal spot urine:third trimester of gestationΣDEHP 4.56 μg/kg_bw/dayanxious/depressed symptomsΣDEHP 8 years: N.AΣDEHP 11 years: N.A ♂/↑ ♀ΣDEHP 14 years: N.A ♂/↑ ♀Chen et al.81Study group, Taiwan.491 children: 245 ♂/246 ♀CBCL3 yearsmaternal spot urine: second trimester of gestationMnBP ♂ 10.489 and ♀ 10.604 μg/ganxious/depressed symptomsassociated with anxious/depressed symptomsHuang et al.82TMICS cohort, Taiwan.408 children: 222 ♂/186 ♀CBCL and DSM-V3 yearsmaternal spot urine: third trimester of gestationMnBP ♂ 22.82 and ♀ 22.83 μg/gMiBP ♂ 11.07 and ♀ 12.94 μg/gdepression problemsMnBP and MiBP: associated with depression problemsTsai et al.83APrON cohort, Canada.351 childrenCBCL and BASC-23–4 yearsmaternal spot urine: second trimester of gestationMBzP 8.13 μg/LMECPP 14.81 μg/LMEOHP 8.45 μg/LMBP 16.66 μg/LMiBP 9.71 μg/LMEHP 3.31 μg/LMEP 17.29 μg/Lanxious/depressed symptomsMEHP, MECPP, and MEP: associated with anxious/depressed symptomsMBzP, MECPP, MEEOHP, MBP, and MiBP: associated with anxietyMiBP: associated with depressionEngland-Mason et al.84CCCEH cohort, USA.250 children: 115 ♂/135 ♀CBCL7–9 yearsmaternal spot urine: third trimester of gestationBPA ♂ 3.2 and♀ 3.4 μg/Lanxious/depressed symptomsBPA: ↑ ♂/N.A ♀Roen et al.85children spot urine: 3 or 5 yearsBPA ♂ 5.4 and ♀ 10.4 μg/LBPA: ↓ ♂/↑ ♀HOME cohort, USA.240 children: 112 ♂/128 ♀BASC-23 yearsmaternal spot urine: 16 and 26 weeks of gestation; <24 h post-deliveryBPA 2.2 μg/ganxiety and depressionBPA: ↑ ♀/N.A ♂Braun et al.86children spot urine: 1, 2, and 3 yearsBPA 14 μg/gBPA: N.AAutism spectrum disorderMIREC cohort, Canada.556 children: 268 ♂/288 ♀SRS-23–4 yearsmaternal spot urine: first trimester of gestationMBP ♂ 14.2 and ♀ 11.5 μg/LMCPP ♂ 1.06 and ♀ 0.90 μg/LASD-related behaviorsMBP and MCPP: ↑ ♂/N.A ♀Oulhote et al.87Study group, Turkey.51 autistic children50 control childrenDSM-IV6 yearsplasma:6 yearsBPA 2.15 and 1.12 ng/mLhigh levels of plasticizers in ASD patientsno differencesKondolot et al.88DEHP 0.198 and 0.172 ng/mLMEHP 0.068 and 0.088 ng/mLStudy group, USA.50 autistic children53 control childrenDSM-IV11 yearschildren spot urine: 11 yearsMEHP 20.18 and 15.80 ng/mLhigh levels of plasticizers in ASD patientsno differencesStein et al.895-oxo MEHP 5.31 and 5 ng/mL5-OH MEHP 10.84 and 10.66 ng/mL5-cx MEPP 433.89 and 341.06 ng/mLMIREC cohort, Canada.478 children: 235 ♂/243 ♀SRS-23–4 yearsmaternal spot urine: first trimester of gestationBPA 0.84 μg/LASD-related behaviorsBPA, MBP, and MCPP: ↑↑ ♂/↑ ♀MEP: ↓ ♂/↓ ♀Alampi et al.90MBP 12.7 μg/LMBzP 5.45 μg/LMCPP 0.89 μg/LMEHHP 9.55 μg/LMEHP 2.34 μg/LMEOHP 6.78 μg/LMEP 32.2 μg/LΣDEHP 18.8 μg/LEARLI cohort, USA.140 children: 77 ♂/63 ♀SRS3 yearsmaternal spot urine: first, second, and third trimester of gestationMCPP 2.10 ng/mLMiBP 9.35 ng/mLMBzP 6 ng/mLMBP 13.10 ng/mLMEP 26.95 ng/mLASD-related behaviorsN.APatti et al.91HOME cohort, USA.276 children: 123 ♂/153 ♀SRS4–8 yearsmaternal spot urine: 16 and 26 weeks of gestationMCPP 3.36 ng/mLMiBP 5 ng/mLMBzP 9.36 ng/mLMBP 23.40 ng/mLMEP 117.48 ng/mLASD-related behaviorsMCPP: ↑ ♂/N.A ♀MiBP, MBzP, MBP, and MEP: ↑↑ ♂/↑ ♀MABC cohort, China.3,209 children: 1,639 ♂/1,570 ♀CHAT-23 and CABS1.5, 3, 5, and 6 yearsmaternal spot urine: first, second, and third trimester of gestation1.5 years: MEP 6.72 μg/g, MEHHP 7.16 μg/g3 years: MMP 18.76 μg/g, MEHP 4.31 μg/g, MEOHP 8.75 μg/g5 years: MMP and MEHP6 years: MMPASD-related behaviorsassociated1.5 years: MEP and MEHHP3 years: MMP, MEHP, and MEOHP5 years: MMP and MEHP6 years: MMPGao et al.92Study group, Turkey.48 autistic children41 control childrenDSM-IV3–12 yearsserum samples: 3–12 yearsMEHP 0.47 and 0.29 μg/mLDEHP 2.70 and 1.62 μg/mLBPA 1.25 and 0.88 ng/mLhigh levels of plasticizers in ASD patientsMEHP, DEHP, and BPA: ↑ ASDKardas et al.93OCC cohort, Denmark.425 children: 223 ♂/202 ♀CBCL2 and 5 yearsmaternal spot urine: 28 weeks of gestationBPA 1.2 ng/mLASD-related behaviorsBPA 2 years:↑ ♂/↑↑ ♀BPA 5 years:N.AHansen et al.94Attention-deficit/hyperactivity disorderEDC cohort, South Korea.619 children: 325 ♂/294 ♀ARS- IV4,6, and 8 yearschildren spot urine:4, 6, and 8 years4 years:BPA ♂ 3.28 and ♀ 3.3 μg/g6 years:BPA ♂ 2.40 and ♀ 2,33 μg/gBPF ♂ 0.20 and ♀ 0.20 μg/gBPS ♂ 0.09 and ♀ 0.10 μg/g8 years:BPA ♂ 2.07 and ♀ 1.84 μg/gBPF ♂ 0.42 and ♀ 0.39 μg/gBPS ♂ 0.16 and ♀ 0.15 μg/gADHD-related behaviorsBPA 4 years: N.ABPA, BPF, and BPS 6 years:↑ ♂/↑↑ ♀BPA, BPF, and BPS 8 years: N.AKim et al.95CHARGE cohort, USA.225 autistic children236 control childrenABC-ADHD oriented2–5 yearschildren spot urine: 2–5 yearsMBzP 30.4 ng/mLMHPP 1.3 ng/mLMNBP 39.7 ng/mLADHD-related behaviorsMBzP ↑/N.AMHPP ↑/N.AMNBP ↑/N.AOh et al.96South Korea.78 ♂ ADHD children438 ♂ control childrenDSM-IVARS-IV6–15 yearschildren spot urine: 6–15 yearsMEHP 48.18 and 25.30 μg/gMEOP 43.99 and 20.53 μg/gMBP 65.96 and 50.86 μg/ghigh levels of plasticizers on ADHD patientsMEHP ↑ ADHDMEOP ↑ ADHDMBP ↑ ADHDPark et al.97MoBa cohort, Norway.295 ADHD children; 213 ♂/82 ♀551 control children: 273 ♂/278 ♀ICD-10not specifiedmaternal spot urine: 17 weeks of gestationΣDEHP 0.31 and 0.27 μmol/Lodds of ADHDΣDEHP: ↑ ♂/↑↑ ♀Engel et al.98NHANES, USA.460 children: 237 ♂/223 ♀DISC-IV8–15 yearschildren spot urine: 8–15 yearsBPA 3.67 μg/LADHD symptomsBPA: ↑↑ ♂/↑ ♀Tewar et al.99OCC cohort, Denmark.425 children: 223 ♂/202 ♀CBCL2 and 5 yearsmaternal spot urine: 28 weeks of gestationBPA 1.2 ng/mLADHD-related behaviorsBPA: N.AHansen et al.94Turkey.45 ADHD patients: 37 ♂/8 ♀30 control patients: 20 ♂/10 ♀DSM-V6–16 yearsserum samples: 6–16 yearsBPA 304 and 257.03 pg/mLhigh levels of plasticizers on ADHD patientsBPA: ↑ ADHDBaykal et al.100C-ABS cohort, China.1,783 childrenASQ3 and 4 yearsmaternal serum samples: first trimester of gestationBPA 0.23 ng/mLADHD-related behaviorsBPA: ↑ 3 years/N.A 4 yearsHuang et al.101MoBa cohort, Norway.260 ADHD children: 145 ♂/115 ♀549 control children: 275 ♂/274 ♀CBCL and DSM-IV3 yearsmaternal spot urine: 17 weeks of gestationMnBP 20 and 18.1 μg/Lodds of ADHDMnBP: ↑ ♂/N.A ♀Kamai et al.102↑Concentration associated with high symptoms/mental disorder; ↑↑ stronger associated with high symptoms compared to other sex; ↓ concentration associated with lower symptoms; N.A, no associated.CBCL, Child Behavior Checklist; BASC, Behavior Assessment System for Children; HDRS, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; SRS-2, Social Responsiveness Scale-II; ARS, ADHD Rating Scale IV; ICD-10, 10th revision of International Classification of Diseases; DSM, Diagnostic and Statistical Manual of Mental Disorders; CHAT-23, Checklist for Autism in Toddlers; CABS, Clancy Autism Behavior Scale; ASQ, Conners’ Abbreviated Symptom Questionnaire; DISC, Diagnostic Interview Schedule for Children. Bisphenols and phthalates are associated with mental disorders ↑Concentration associated with high symptoms/mental disorder; ↑↑ stronger associated with high symptoms compared to other sex; ↓ concentration associated with lower symptoms; N.A, no associated. CBCL, Child Behavior Checklist; BASC, Behavior Assessment System for Children; HDRS, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; SRS-2, Social Responsiveness Scale-II; ARS, ADHD Rating Scale IV; ICD-10, 10th revision of International Classification of Diseases; DSM, Diagnostic and Statistical Manual of Mental Disorders; CHAT-23, Checklist for Autism in Toddlers; CABS, Clancy Autism Behavior Scale; ASQ, Conners’ Abbreviated Symptom Questionnaire; DISC, Diagnostic Interview Schedule for Children. In the CCCEH cohort, Whyatt et al. reported that prenatal MBzP exposure was associated with anxiety/depression symptoms at age 3, but only in girls.79 Conversely, Kobrosly and colleagues in the SFF cohort observed that higher prenatal concentrations of both the sum of four DEHP metabolites and MBzP were associated with lower anxiety scores in girls aged 6–10.53 In the Taiwan Maternal and Infant Cohort Study (TMICS) cohort, Chen et al. found that prenatal exposure to the sum of DEHP metabolites was associated with anxious/depressed symptoms in girls at ages 11 and 14 but not at age 8.81 Huang et al. reported an association between prenatal MnBP and anxious/depressed symptoms in 3-year-olds, whereas BPA and three other phthalate metabolites were not associated.82 Tsai and collaborators likewise found links between prenatal MnBP and mono isobutyl phthalate (MiBP) and depression problems, but they did not observe associations with anxiety for any of the seven measured phthalate metabolites.83 In the APrON cohort, prenatal concentrations of nine phthalate metabolites were measured in children aged 3–4: Child Behavior Checklist (CBCL) anxiety/depression scores were associated with MEHP, MECPP, and mono ethyl phthalate (MEP); Behavior Assessment System for Children (BASC)-2 anxiety scores were associated with MBzP, MECPP, mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), monobutyl phthalate (MBP), and MiBP; and BASC-2 depression scores were associated only with MiBP.84 Adding another layer, levels of plasticizers were measured across studies on diverse mental disorders. Segovia-Mendoza and collaborators found that 34-year-old patients diagnosed with major depressive disorder had significantly higher serum levels of BPS compared to non-depressed controls.4 There is a growing body of research exploring the impact of plasticizers on the development of anxiety- and depressive-like behaviors in animal models (Table 3). Behavioral paradigms such as the elevated plus maze, the forced swimming test, and the three-chamber social interaction test are commonly used to assess traits analogous to human depression, including hopelessness, lack of motivation, and reduced social engagement. Experimental studies in rodents consistently show that bisphenols and phthalates induce dose- and sex-dependent affective alterations, with males generally exhibiting greater vulnerability. In C57BL/6 mice, perinatal exposure to BPA at both low (10 μg/kg bw/day) and high (10 mg/kg bw/day) doses increased depressive-like behavior selectively in males, in parallel with a reduction in hippocampal serotonin. Fluoxetine reversed depressive behaviors only at the lower BPA dose, suggesting that low-dose effects remain more pharmacologically plastic. These findings align with evidence implicating dehydroepiandrosterone (DHEA)—often reduced in depressed patients—as a neuroprotective modulator acting through gamma-aminobutyric acid (GABA), NMDA, and estrogen receptors, promoting antioxidant responses, suppressing proinflammatory cytokine synthesis, and preserving blood-brain barrier integrity.114,115 Consistent male-biased susceptibility was also observed following gestational exposure to mixtures of bisphenols and phthalates reflecting levels detected in pregnant women, where males displayed increased depressive-like behaviors and upregulation of stress-related genes (Crh and reduced Nr3c1) across the hippocampus, hypothalamus, and amygdala, indicative of heightened HPA axis activation. Females showed milder behavioral changes, accompanied by compensatory molecular adaptations, including increased Nr3c1 and oxytocin receptor (Oxtr) expression in the amygdala, which may buffer anxiety-related phenotypes.Table 3Effects of bisphenols and phthalates on mental disorders evaluated in animal modelsModelSexTestStagePlasticizer concentration (median)Main outcomeMolecular alterationsReferenceAnxiety/depressionMouse C57BL/6♂ ♀FSTPNBPA (10 μg/kg bw/day [lower dose] or 10 mg/kg bw/day)↑ depressive-like behavior only in ♂↓ hippocampal serotonin↓DHEA in serumXin et al.103MouseC57BL/6♂ ♀EPMTOFTSITNOLFSTPNphthalates and bisphenols (0.001, 0.22, 2.2 or 11 mg/kg bw/day) pregnant ♀ mixture (DEP, DBP,BBzP, DIDP, BPA, TCP, 3PBA, and p,p’-DDE)↑ depressive-like behavior only in ♂↑↓ hypothalamus and hippocampal gene expression involved in stress only in ♂ (Nr3c1, Crh, Fkbp5, Oxt, and Esr2)Repouskou et al.25Mouse C57BL/6not reportedEPMTOFTTSTSPTFSTPoNBPA (0.5 mg/kg/day)21 to 80 PND↑ depressive- and anxiety-like behavior↑ microglia activation↑ proinflammatory cytokines in mPFC (IL-1b and TNF-α)Wang et al.104Mouse C57BL/6not reportedOFTEPMTSTFSTPoNBPF (10, 40, 160 μg/kg/day) 30 days↑depressive- and anxiety-like behavior in all doses↑ synaptic markers proteins (PSD95 and SYN)↓kynurenic acidLin et al.105C57BL/6 mousenot reportedEPMTOFTFSTPN5, 50, 200 mg/kg/day DEHPdepressive- and anxiety-like behavior only in males in all doses↓ free triiodothyronine (only in males), receptors, transporters, and metabolic enzymes in fetal brainLv et al.106Attention-deficit/hyperactivity disorderWistar ratsnot reportedLARESNGRNeo40 mg/rat↑ADHD-like behaviornot measurementKiguchi et al.107C57BL/6 mouse♂OFTLATEPMTOFT SITPNDMEP 50 mg/kg/day↑ Hyperactivity and anxiety-like behavior↓ neuronal number in the parietal cortex↓ expression of genes involved in neurogenesis and cortical development (e.g., Npy, Scn1b, Mdga2, Meis1, Adra2c, Rgs6, and Ntm)Ko et al.108ICR mouse♂not applyPNBPA 5 mg/kg/day andDEHP 1 mg/kg/daynot measurement↓ neuronal dopaminergic neurons (tyrosine hydroxylase)Tanida et al.109Autism spectrum disorderWistar Furth rats♀♂OFTGD 0 to birth (PNl)BPA 5,000 μg/kg/day↑ social novelty in ♀↓ Sema5a, Slc9a9 (♂)↓ Anxa2, Junb (♀)Kanlayaprasit et al.110Wistar rats♀♂not applyGD1 to birth; NSCs at PoN 1BPA 5,000 μg/kg/daynot apply↓↑ Atp1a3, Nefl, Grin1, Gabrb1, L1cam; altered GABAergic/glutamatergic signaling, neurogenesis, and synaptic plasticity pathways (more robust in ♂)Kasitipradit et al.111Wistar rats♂SITOFTREE 1 to PoN 23 (pregnancy + lactation)DEHP 0.1, 1, 10, 100 mg/kg/day (VPA as positive control)↓ social noveltyincreased↑repetitive behaviors and anxiety↑ p-AKT, p-mTOR ↑hippocampal neuronal damage↓ autophagy, LC3-II, Beclin1, and autophagosomesLi et al.112Human and mouse♀♂OFThuman: PNmice: E10.5–E14.5 (mid-GS)BPA 50 μg/kg/day in mice according with human prenatal BPA levels↑ ASD symptoms in boys with low aromatase activity↑ASD-like behaviors in ♂ Mi↓ aromatase in amygdala↑ methylation of CYP19A1↓ synaptogenesis and CREBdisruptedSymeonides et al.113EPMT, elevated plus maze test; OFT, open field test; SIT, social interaction test; NOL, novel object location test; FST/TST, forced swim test/tail suspension test; SPT, sucrose preference test; LA, locomotor activity; RE, rearing; SN, sniffing; GR, grooming; PN, prenatal; PoN, postnatal; Neo, neonatal; GS, gestational day. Table 3Effects of bisphenols and phthalates on mental disorders evaluated in animal modelsModelSexTestStagePlasticizer concentration (median)Main outcomeMolecular alterationsReferenceAnxiety/depressionMouse C57BL/6♂ ♀FSTPNBPA (10 μg/kg bw/day [lower dose] or 10 mg/kg bw/day)↑ depressive-like behavior only in ♂↓ hippocampal serotonin↓DHEA in serumXin et al.103MouseC57BL/6♂ ♀EPMTOFTSITNOLFSTPNphthalates and bisphenols (0.001, 0.22, 2.2 or 11 mg/kg bw/day) pregnant ♀ mixture (DEP, DBP,BBzP, DIDP, BPA, TCP, 3PBA, and p,p’-DDE)↑ depressive-like behavior only in ♂↑↓ hypothalamus and hippocampal gene expression involved in stress only in ♂ (Nr3c1, Crh, Fkbp5, Oxt, and Esr2)Repouskou et al.25Mouse C57BL/6not reportedEPMTOFTTSTSPTFSTPoNBPA (0.5 mg/kg/day)21 to 80 PND↑ depressive- and anxiety-like behavior↑ microglia activation↑ proinflammatory cytokines in mPFC (IL-1b and TNF-α)Wang et al.104Mouse C57BL/6not reportedOFTEPMTSTFSTPoNBPF (10, 40, 160 μg/kg/day) 30 days↑depressive- and anxiety-like behavior in all doses↑ synaptic markers proteins (PSD95 and SYN)↓kynurenic acidLin et al.105C57BL/6 mousenot reportedEPMTOFTFSTPN5, 50, 200 mg/kg/day DEHPdepressive- and anxiety-like behavior only in males in all doses↓ free triiodothyronine (only in males), receptors, transporters, and metabolic enzymes in fetal brainLv et al.106Attention-deficit/hyperactivity disorderWistar ratsnot reportedLARESNGRNeo40 mg/rat↑ADHD-like behaviornot measurementKiguchi et al.107C57BL/6 mouse♂OFTLATEPMTOFT SITPNDMEP 50 mg/kg/day↑ Hyperactivity and anxiety-like behavior↓ neuronal number in the parietal cortex↓ expression of genes involved in neurogenesis and cortical development (e.g., Npy, Scn1b, Mdga2, Meis1, Adra2c, Rgs6, and Ntm)Ko et al.108ICR mouse♂not applyPNBPA 5 mg/kg/day andDEHP 1 mg/kg/daynot measurement↓ neuronal dopaminergic neurons (tyrosine hydroxylase)Tanida et al.109Autism spectrum disorderWistar Furth rats♀♂OFTGD 0 to birth (PNl)BPA 5,000 μg/kg/day↑ social novelty in ♀↓ Sema5a, Slc9a9 (♂)↓ Anxa2, Junb (♀)Kanlayaprasit et al.110Wistar rats♀♂not applyGD1 to birth; NSCs at PoN 1BPA 5,000 μg/kg/daynot apply↓↑ Atp1a3, Nefl, Grin1, Gabrb1, L1cam; altered GABAergic/glutamatergic signaling, neurogenesis, and synaptic plasticity pathways (more robust in ♂)Kasitipradit et al.111Wistar rats♂SITOFTREE 1 to PoN 23 (pregnancy + lactation)DEHP 0.1, 1, 10, 100 mg/kg/day (VPA as positive control)↓ social noveltyincreased↑repetitive behaviors and anxiety↑ p-AKT, p-mTOR ↑hippocampal neuronal damage↓ autophagy, LC3-II, Beclin1, and autophagosomesLi et al.112Human and mouse♀♂OFThuman: PNmice: E10.5–E14.5 (mid-GS)BPA 50 μg/kg/day in mice according with human prenatal BPA levels↑ ASD symptoms in boys with low aromatase activity↑ASD-like behaviors in ♂ Mi↓ aromatase in amygdala↑ methylation of CYP19A1↓ synaptogenesis and CREBdisruptedSymeonides et al.113EPMT, elevated plus maze test; OFT, open field test; SIT, social interaction test; NOL, novel object location test; FST/TST, forced swim test/tail suspension test; SPT, sucrose preference test; LA, locomotor activity; RE, rearing; SN, sniffing; GR, grooming; PN, prenatal; PoN, postnatal; Neo, neonatal; GS, gestational day. Effects of bisphenols and phthalates on mental disorders evaluated in animal models EPMT, elevated plus maze test; OFT, open field test; SIT, social interaction test; NOL, novel object location test; FST/TST, forced swim test/tail suspension test; SPT, sucrose preference test; LA, locomotor activity; RE, rearing; SN, sniffing; GR, grooming; PN, prenatal; PoN, postnatal; Neo, neonatal; GS, gestational day. Additional models highlight the involvement of neuroinflammation, synaptic dysfunction, and endocrine disruption. Postnatal BPA exposure (0.5 mg/kg/day, PND 21–80) increased depressive- and anxiety-like behaviors, associated with prefrontal cortex hyperactivation, microglial release of IL-1β and TNF-α, and reduced IL-10, leading to impaired neurogenesis and synaptic plasticity.116 Exposure to bisphenol F (BPF) at environmentally relevant doses (10–160 μg/kg/day) induced depressive-like behavior across all concentrations, concomitant with reduced prefrontal and hippocampal synaptic activity and decreased kynurenic acid, a key neuroprotective metabolite of the tryptophan pathway.105,117 Similarly, treatment with DEHP (5–200 mg/kg/day) produced depressive- and anxiety-like behaviors predominantly in males, while females exhibited anxiety only at the highest dose. These effects were accompanied by a male-specific reduction in fetal triiodothyronine (T3) and decreased thyroid hormone receptors and transporters in both sexes, linking phthalate-induced thyroid disruption to impaired neurogenesis and reduced serotonergic sensitivity—mechanisms closely associated with depressive phenotypes.118 ADHD ADHD is a chronic neurodevelopmental disorder characterized by persistent inattention and/or hyperactivity-impulsivity, which has a direct negative impact on academic, occupational, or social functioning.119 Systematic reviews have estimated the worldwide prevalence of ADHD to be between 2% and 7%, averaging around 5% in children and adolescents.53,120 There is mainstay evidence of high heritability of ADHD, but environmental factors are also involved in its development, such as exposure to plasticizers, especially during the prenatal period. However, the effects and findings with bisphenols and phthalates are inconsistent (Table 2). Hansen et al. in the OCC cohort found no association between prenatal exposure to high BPA levels and ADHD in boys or girls at ages 2 and 5.94 Kim and colleagues in the EDC cohort reported that childhood urinary concentrations of BPA, BPF, and BPS at age 6 were associated with higher ADHD symptom scores, with stronger effects in girls than in boys.95 In the National Health and Nutrition Examination Survey (NHANES), higher urinary BPA concentrations in children aged 8–15 were linked to elevated ADHD symptom counts, and the association was stronger in boys.99 In the C-ABS cohort, Huang and colleagues found that maternal serum BPA was associated with ADHD-related behaviors at age 3 but not at age 4; sex-stratified analyses at age 4 showed no associations.101 Oh et al. in the CHARGE cohort did not find associations between childhood urinary concentrations of six bisphenols measured at ages 2–5 and ADHD. Interestingly, several phthalate metabolites, including ΣDEHP, MBzP, MHPP, and MnBP, were associated with ADHD symptoms exclusively in children with ASD and not in control groups.96 In the MoBa cohort, Kamai et al. observed that MnBP was associated with higher odds of ADHD at age 3 in boys but not in girls; no associations were seen for other four measured phthalate metabolites or for ΣDEHP and Σdiisononyl phthalate (DINP).102 Adding to it, also in MoBa, Engel and team found that ΣDEHP was associated with an increased risk of ADHD in offspring, whereas exposure to ΣDINP and four other metabolites showed no association.98 Park et al. reported that spot urine concentrations of MEHP, mono(2 ethyl 5 oxohexyl) phthalate (MEOP), and MBP were higher in boys diagnosed with ADHD aged 6–15 than boys with typical development.97 Finally, Baykal and collaborators found that serum BPA concentrations were higher in ADHD-diagnosed patients aged 6–16 than in controls.100 Experimental evidence from animal models supports a mechanistic link between early-life exposure to plasticizers and neurodevelopmental alterations relevant to ADHD, with clear roles for dose, timing, and sex, as well as convergent disruption of dopaminergic and cortical developmental pathways (Table 3). In a C57BL/6N mouse model, prenatal and early postnatal exposure to di-methoxyethyl phthalate (DMEP) at 50 mg/kg/day—a dose corresponding to the developmental lowest observed adverse effect level (LOAEL)—induced persistent ADHD-like phenotypes, including increased locomotor activity and reduced anxiety-like behavior, without major sociability deficits.108 These behavioral alterations were accompanied by marked cortical developmental defects, including reduced cortical thickness, decreased neuronal density in the parietal cortex, and increased astrocyte numbers, indicating a shift in neurodevelopmental trajectories. At the synaptic level, DMEP exposure impaired both excitatory and inhibitory connectivity, with reduced VGLUT and VGAT puncta, altered dendritic spine maturation (loss of mushroom and stubby spines and increase in immature filopodia), and decreased neuronal network activity. Transcriptomic analyses revealed downregulation of genes involved in neurogenesis and cortical patterning (e.g., Npy, Scn1b, Mdga2, Meis1, and Adra2c) and upregulation of the gliogenic regulator Hes5, suggesting a premature shift from neuronal to glial fate during development. Although behavioral analyses were conducted mainly in males, the lack of systematic sex comparisons represents a limitation, particularly given known sexual dimorphism in endocrine disruption. Complementary evidence from ICR mice further highlights the sensitivity of dopaminergic systems to plasticizer exposure during critical developmental windows.109 Fetal and neonatal exposure to BPA (5 mg/kg/day), DEHP (1 mg/kg/day), or 2,3,7,8 tetrachloro di benzo-p-dioxin (TCDD) (8 ng/kg)—all at doses below NOAEL or LOAEL—led to reduced body and brain weight, decreased numbers of tyrosine hydroxylase (TH)-positive dopaminergic neurons, and altered Fos expression in midbrain nuclei, indicative of impaired dopamine biosynthesis and long-term changes in neuronal responsiveness. Notably, these effects were observed following single-compound exposures, whereas mixture exposure (BPA + DEHP + TCDD) unexpectedly abolished most neurodevelopmental alterations, suggesting antagonistic interactions between endocrine-disrupting pathways, potentially involving crosstalk between thyroid hormone signaling and aryl hydrocarbon receptor (AHR) pathways. Mechanistically, these findings align with broader evidence showing that BPA reduces dopamine receptors and transporters129 and increases hyperactivity and locomotion when administered centrally107 and that DEHP or dibutyl phthalate (DBP) exposure alters dopamine-related gene expression and spontaneous motor activity.130 Together, these studies underscore that early-life exposure to specific plasticizers, even at low or regulatory-relevant doses, can disrupt cortical and dopaminergic development, producing long-lasting behavioral phenotypes consistent with ADHD, while also emphasizing the importance of sex as a biological variable and mixture effects in neurotoxicological risk assessment. ASD ASD encompasses a wide range of neurodevelopmental conditions characterized by challenges in social interaction, communication, and restricted or repetitive behaviors.119 Current estimates suggest that about 1 in 59 children is diagnosed with ASD, with boys being four times more likely to be diagnosed than girls; still, global prevalence rates continue to rise.131,132 While the causes of ASD remain complex, principally attributed to genetic background, some research has explored potential links between environmental factors, such as exposure to plasticizers, and ASD risk. However, findings are mixed (Table 2). Cohort studies showed associations between prenatal exposure to high levels of phthalates and their metabolites and autistic-like behavior. Oulhote et al. in the MIREC cohort reported that higher gestational concentrations of MBP and MCPP were associated with ASD-related behaviors in boys aged 3–4 but not in girls, and they found no associations with two other phthalates or ΣDEHP.87 Also in the MIREC cohort, Alampi and colleagues found that higher prenatal urinary levels of MCPP, MBP, and BPA were associated with increased autistic-like behaviors in children aged 3–4, with stronger associations in boys; conversely, MEP, was strongly associated with decreased autistic-like behaviors, and no associations were seen for other four measured metabolites or ΣDEHP.90 Patti and collaborators examined two cohorts and five prenatal phthalate metabolites: in EARLI, 3-year-olds showed no association with ASD-related behaviors; in HOME, among children aged 4–8, MCPP was associated with increased ASD behaviors in both sexes, but with stronger effects in boys.91 In the MABC cohort, Gao et al. measured gestational concentrations of seven phthalate metabolites and ΣDEHP across the three trimesters using spot urine samples and assessed associations at ages 1.5, 3.5, and 6 years: at 1.5 years, MEP and mono(2 ethyl 5 hydroxyhexyl) phthalate (MEHHP) were associated with ASD-related behaviors; at 3 years, MMP, MEHP, and MEOHP were associated; and at 6 years, only MMP was associated.92 In the OCC cohort, Hansen found that prenatal BPA concentrations were associated with ASD-related behaviors in 2-year-old children, with stronger effects in girls, but no association was observed at age 5 in either sex.94 Finally, phthalates and bisphenols have been measured directly in individuals with ASD. Stein et al. found no differences in urinary MEHP levels between 11-year-old children with ASD and typically developing controls.89 Kondolot and collaborators reported no differences in plasma BPA, DEHP, and MEHP levels between 6-year-old autistic and healthy children.88 By contrast, Kardas et al. measured the same plasticizers but in serum of diagnosed autistic patients aged 3–12 and reported higher concentrations of all three plasticizers in ASD patients compared with typically developing children.93 The levels of phthalates in autistic children may be associated with their behavior of tending to interact with plastic toys or similar items. Given the considerable heterogeneity of signs and symptoms across the autism spectrum, animal models have primarily focused on genetic mutations and copy number variants associated with autism-related behaviors, as well as environmental factors that may exacerbate these traits (Table 3). Behavioral assays commonly employed to evaluate autism-like phenotypes include the three-chamber social approach task (for assessing social interaction), the tube test (for evaluating social dominance), ultrasonic vocalization analysis (as a measure of communication deficits), and grooming behavior (as an indicator of anxiety-like behavior), among others.133 Prenatal exposure to BPA has been shown to impair social interaction and significantly increase grooming behavior in mice, features often linked to heightened anxiety. These effects are more prominent in males, suggesting a potential modulatory role of sex steroids.113 Across recent experimental studies, prenatal and perinatal exposure to common plasticizers has emerged as a biologically plausible contributor to ASD, with consistent evidence for sex-specific vulnerability. In an animal study, pregnant dams were orally exposed to BPA from gestational day 0 until birth at 5,000 μg/kg/day, a dose corresponding to the regulatory No observed adverse effect level (NOAEL). Both male and female offspring were examined. The main outcome revealed striking sex-dependent effects: males showed increased neurogenesis without overt social deficits, accompanied by reduced expression of Sema5a and Slc9a9, genes implicated in cortical wiring and social behavior, whereas females exhibited reduced neurite outgrowth and impaired social novelty, associated with downregulation of Anxa2 and Junb, suggesting fundamentally different molecular responses to identical BPA exposure that may underlie sex-biased ASD phenotypes.110 Complementary work focusing on neural stem cells (NSCs) from the hippocampus of Wistar rats further supports this concept. In this model, maternal oral BPA exposure from gestational day 1 to delivery at 5,000 μg/kg/day again targeted a critical developmental window. NSCs isolated at postnatal day 1 were analyzed. Male-derived NSCs showed stronger enrichment of ASD-associated genes, including Atp1a3, Nefl, Grin1, Gabrb1, and L1cam, and disruption of GABAergic and glutamatergic signaling pathways, neurogenesis, and synaptic plasticity. These findings indicate that BPA exposure during early development can reprogram stem cell behavior in a sex-dependent manner, potentially biasing long-term ASD risk.111 Beyond BPA, similar principles have been demonstrated for other plasticizers. In a Wistar rat model of ASD predominantly examining male offspring, perinatal exposure to DEHP occurred via maternal oral administration from embryonic day 1 through postnatal day 23, encompassing both pregnancy and lactation, at doses ranging from 0.1 to 100 mg/kg/day. They observed that the higher dose of DEHP induced robust ASD-like behaviors, including reduced sociability, impaired social novelty, increased repetitive actions, and heightened anxiety. At the molecular level, these behavioral changes were linked to activation of the mTOR signaling pathway, hippocampal neuronal damage, and suppressed autophagy, evidenced by reduced LC3-II, Beclin1, and autophagosome formation, highlighting disruption of the mTOR-autophagy axis as a central mechanism.112 Finally, a large multimodal human-animal study provided mechanistic depth by linking prenatal BPA exposure to aromatase disruption, offering a unifying explanation for male-biased ASD susceptibility. In the Barwon Infant Study cohort, higher prenatal BPA levels were associated with increased ASD symptoms at age 2 and clinical diagnosis at age 9, exclusively in boys with low genetic aromatase activity, alongside hypermethylation of the brain-specific CYP19A1 and downstream brain-derived neurotrophic factor (BDNF) hypermethylation. Parallel mouse experiments, involving mid-gestation BPA exposure at 50 μg/kg/day, demonstrated that male offspring developed ASD-like social and repetitive behaviors, accompanied by amygdala and cortical structural deficits, reduced dendritic complexity, altered synaptic activity, and suppressed aromatase expression. Notably, these phenotypes closely mirrored those observed in aromatase knockout mice. Importantly, postnatal treatment with 10-hydroxy-2-decenoic acid reversed behavioral, neuroanatomical, electrophysiological, and transcriptomic alterations, restoring pathways related to synaptogenesis, cAMP response element-binding protein (CREB) signaling, and neurite growth, indicating that aromatase-dependent estrogen signaling is a critical, and potentially reversible, molecular node linking BPA exposure to ASD risk in males.113 The evidence summarized in the previous section highlights the neurodevelopmental and neuropsychiatric risks associated with bisphenol and phthalate exposure, as demonstrated by epidemiological associations in humans and causal findings in experimental animal models. Building on these findings, a critical area of research has emerged, focusing on identifying strategies to attenuate or reverse the neurotoxic effects induced by these plasticizers. Accordingly, the following section addresses experimental evidence showing that certain compounds, both synthetic and natural, can mitigate plasticizer-induced neurotoxicity. Overall, the available evidence indicates that exposure to bisphenols and phthalates is consistently associated with neurobehavioral alterations, including anxiety, depression, ADHD, and ASD, driven by convergent mechanisms such as endocrine disruption, neuroinflammation, and alterations in serotonergic and dopaminergic systems, particularly within the hippocampus and prefrontal cortex. However, the magnitude and direction of these effects vary depending on sex, dose, exposure window, and the specific metabolite evaluated, contributing to the heterogeneity observed across epidemiological studies and experimental models. In this context, these discrepancies should not be interpreted as contradictory findings but rather as the result of interacting biological and methodological determinants. Mitigation of neurotoxicity Certain compounds have been shown, in preclinical in vitro and in vivo studies, to mitigate or reverse the neurotoxic effects induced by exposure to plasticizers, primarily through modulation of oxidative stress, inflammatory pathways, and hormone levels (Figure 4). These compounds can be of synthetic or natural origin, including plant extracts. Their effectiveness depends on various factors, such as the timing of administration (pre-exposure, post-exposure, or co-administration), the route of administration (e.g., injection, oral intake, or incorporation into food), and the administered dose (Table 4). Some of the previously described neurotoxic effects are sex specific or developmentally dependent. The efficacy of these compounds has been described experimentally in both in vivo and in vitro models. Although the effect has been established, it is not clinically proven, and it does not constitute a medical recommendation.Figure 4Mitigation of neurotoxicityOverview of evidence in preclinical in vitro and in vivo studies showing that synthetic and natural compounds can attenuate or reverse neurotoxic effects induced by bisphenols and phthalates. Chronic exposure to these plasticizers promotes oxidative stress, neuroinflammation, apoptosis, and neurotransmission alterations, leading to cognitive and behavioral deficits. Antioxidants and bioactive compounds—such as curcumin, alpha-lipoic acid, nimodipine, vitamin E, morin, naringin, and mushroom-derived extracts—exert neuroprotective effects depending on dose, timing, route of administration, and sex or developmental stage. Created in https://BioRender.com.Table 4Protective effects of compounds against plasticizer-induced toxicity: Doses and outcomesCompound and dose administrationPlasticizer and dose administrationModel/cell lineCompound effect on plasticizer-induced changes (per tissue/cell line)ReferenceAlpha-lipoic acid (50 mg/kg/day, p.o.) 1 h before BPABPA (30 mg/kg/day, p.o.) for 4 weeksmale C57BL/6J mice (8 weeks old)↑ memory↑ exploration behavior↓ muscle coordination defects↑ grip strength↓ lipid peroxidation and protein oxidation in brain tissueKhan et al.121Pretreated with alpha-lipoic acid (100 μM)BPA (30 μM)mouse astrocyte type I cells (C8-DIA)↓ cell loss↓ shortened cell processes↓ cell shrinkage↓ cell death↓ GFAP expression↓ ROSCurcumin (20 mg/kg/day, i.p.) in pups from PND7 to PND28BPA (40 μg/kg bw/day, p.o.) in mothers from GD6 to PND28pup male and female Wistar rats↑ learning and memory via conditioned avoidance response↑ proliferative cells in hippocampus↑ neurogenesis↓ apoptosis↑ activation of proliferative pathwaysTiwari et al.122Curcumin (0.5 μM)BPA (100 μM)primary hippocampal neural stem cells from pups↑ NSC proliferation↓ glial cells↓ morphological changes↑ neuronal fibersAuricularia polytricha (AP) extractHexane AP (5, 10 μg/mL)Ethanol AP (2.5, 5 μg/mL)BPA (5 μM)mouse microglial cells BV2 and mouse hippocampal cells HT-22↓ proinflammatory cytokines in microglial cells↓ oxidative stress in hippocampusSillapachaiyaporn et al.123Pre-treated with alpha-lipoic acid (150 μM) for 4 hBPA (100 μM)mouse hippocampal cells HT-22↓ hippocampal oxidative stress↑ signaling pathway involved in memory consolidation and proliferationWu et al.124Nimodipine (2 mg/kg/day, i.p.) 30 min prior to DBP and vitamin E (50 mg/kg/day, p.o.) 2 h after DBPDBP (50 mg/kg/day, p.o.) for 4 weeksmale Kunming mice (3 weeks old)↑ brain coefficient↓ escape latency on the Morris water maze↓oxidative stress↓ apoptosis and viability↓ deformed, swollen, and disarranged pyramidal cells↓ shortened apical dendrites↑ signaling pathway involved in memory consolidation↓ signaling pathway involved in proliferationYan et al.125Nimodipine (2 mg/kg/day, i.p.) 30 min prior DBPDBP (50 mg/kg/day, p.o.) for 4 weeksmale Kunming mice(3 weeks old)↓ signaling pathway involved in proliferation↓ swollen and deformed cells↓ shortening or eradication of apical tree mutation↓ loss of Nissl bodies↓ apoptosis in hippocampal cellsYan et al.126Nanomicellar curcumin (25, 50 mg/kg/day, p.o.) 1 h prior BPABPA (50 mg/kg/day, p.o.) for 4 weeksmale Wistar rats (8 weeks old)↑ fear learning and memory↓ anxiety-like behavior↑ peripheral and total locomotor activity↓ central locomotory activity↓ oxidative stress↓ proinflammatory cytokines↓hippocampal signaling pathway related to apoptosisFallahnezhad et al.25Morin (25, 50 mg/kg/day, p.o.)BPS (200 μg/kg bw/day, p.o.) and DEP (50 μg/kg bw/day, p.o.) for 3 weeksmale Wistar rats(8 weeks old)↓ neurobehavioral deficits↓ anxiety behavior↑ hippocampus volume↑ total neuron count↓ oxidative stress↓ proinflammatory cytokinesUgwor et al.127Naringin (80 mg/kg/day, p.o.) on co-treatment with BPABPA (50 mg/kg/day, p.o.) for 2 weeksadult male albino ratsocular:↓ neurotransmitter (AChE, BuChE, and MAO-A)↓oxidative stress↓ inflammatory T lymphocytes↓ apoptosisAkintunde et al.128i.p., intraperitoneal; p.o., orally; ↑ increase; ↓ reduce. Mitigation of neurotoxicity Overview of evidence in preclinical in vitro and in vivo studies showing that synthetic and natural compounds can attenuate or reverse neurotoxic effects induced by bisphenols and phthalates. Chronic exposure to these plasticizers promotes oxidative stress, neuroinflammation, apoptosis, and neurotransmission alterations, leading to cognitive and behavioral deficits. Antioxidants and bioactive compounds—such as curcumin, alpha-lipoic acid, nimodipine, vitamin E, morin, naringin, and mushroom-derived extracts—exert neuroprotective effects depending on dose, timing, route of administration, and sex or developmental stage. Created in https://BioRender.com. Table 4Protective effects of compounds against plasticizer-induced toxicity: Doses and outcomesCompound and dose administrationPlasticizer and dose administrationModel/cell lineCompound effect on plasticizer-induced changes (per tissue/cell line)ReferenceAlpha-lipoic acid (50 mg/kg/day, p.o.) 1 h before BPABPA (30 mg/kg/day, p.o.) for 4 weeksmale C57BL/6J mice (8 weeks old)↑ memory↑ exploration behavior↓ muscle coordination defects↑ grip strength↓ lipid peroxidation and protein oxidation in brain tissueKhan et al.121Pretreated with alpha-lipoic acid (100 μM)BPA (30 μM)mouse astrocyte type I cells (C8-DIA)↓ cell loss↓ shortened cell processes↓ cell shrinkage↓ cell death↓ GFAP expression↓ ROSCurcumin (20 mg/kg/day, i.p.) in pups from PND7 to PND28BPA (40 μg/kg bw/day, p.o.) in mothers from GD6 to PND28pup male and female Wistar rats↑ learning and memory via conditioned avoidance response↑ proliferative cells in hippocampus↑ neurogenesis↓ apoptosis↑ activation of proliferative pathwaysTiwari et al.122Curcumin (0.5 μM)BPA (100 μM)primary hippocampal neural stem cells from pups↑ NSC proliferation↓ glial cells↓ morphological changes↑ neuronal fibersAuricularia polytricha (AP) extractHexane AP (5, 10 μg/mL)Ethanol AP (2.5, 5 μg/mL)BPA (5 μM)mouse microglial cells BV2 and mouse hippocampal cells HT-22↓ proinflammatory cytokines in microglial cells↓ oxidative stress in hippocampusSillapachaiyaporn et al.123Pre-treated with alpha-lipoic acid (150 μM) for 4 hBPA (100 μM)mouse hippocampal cells HT-22↓ hippocampal oxidative stress↑ signaling pathway involved in memory consolidation and proliferationWu et al.124Nimodipine (2 mg/kg/day, i.p.) 30 min prior to DBP and vitamin E (50 mg/kg/day, p.o.) 2 h after DBPDBP (50 mg/kg/day, p.o.) for 4 weeksmale Kunming mice (3 weeks old)↑ brain coefficient↓ escape latency on the Morris water maze↓oxidative stress↓ apoptosis and viability↓ deformed, swollen, and disarranged pyramidal cells↓ shortened apical dendrites↑ signaling pathway involved in memory consolidation↓ signaling pathway involved in proliferationYan et al.125Nimodipine (2 mg/kg/day, i.p.) 30 min prior DBPDBP (50 mg/kg/day, p.o.) for 4 weeksmale Kunming mice(3 weeks old)↓ signaling pathway involved in proliferation↓ swollen and deformed cells↓ shortening or eradication of apical tree mutation↓ loss of Nissl bodies↓ apoptosis in hippocampal cellsYan et al.126Nanomicellar curcumin (25, 50 mg/kg/day, p.o.) 1 h prior BPABPA (50 mg/kg/day, p.o.) for 4 weeksmale Wistar rats (8 weeks old)↑ fear learning and memory↓ anxiety-like behavior↑ peripheral and total locomotor activity↓ central locomotory activity↓ oxidative stress↓ proinflammatory cytokines↓hippocampal signaling pathway related to apoptosisFallahnezhad et al.25Morin (25, 50 mg/kg/day, p.o.)BPS (200 μg/kg bw/day, p.o.) and DEP (50 μg/kg bw/day, p.o.) for 3 weeksmale Wistar rats(8 weeks old)↓ neurobehavioral deficits↓ anxiety behavior↑ hippocampus volume↑ total neuron count↓ oxidative stress↓ proinflammatory cytokinesUgwor et al.127Naringin (80 mg/kg/day, p.o.) on co-treatment with BPABPA (50 mg/kg/day, p.o.) for 2 weeksadult male albino ratsocular:↓ neurotransmitter (AChE, BuChE, and MAO-A)↓oxidative stress↓ inflammatory T lymphocytes↓ apoptosisAkintunde et al.128i.p., intraperitoneal; p.o., orally; ↑ increase; ↓ reduce. Protective effects of compounds against plasticizer-induced toxicity: Doses and outcomes i.p., intraperitoneal; p.o., orally; ↑ increase; ↓ reduce. The central nervous system (CNS), particularly the hippocampus, is highly vulnerable to the neurotoxic effects of EDCs such as bisphenols and phthalates. Chronic exposure to these plasticizers induces oxidative stress, neuroinflammation, and apoptosis, leading to cognitive and behavioral deficits. Studies in male rodents demonstrate that co-administration or pretreatment with antioxidants can mitigate these effects. For instance, oral curcumin reversed BPA-induced hippocampal damage in postnatal rats, restoring neurogenesis and reducing apoptosis,122 while co-administration of curcumin with BPA in adult rats improved oxidative stress, inflammation, and spatial memory deficits.25 Also, intraperitoneal alpha-lipoic acid (ALA) before BPA exposure alleviated oxidative stress and acetylcholinesterase (AChE) dysfunction in rats.121 In mice, pretreatment with nimodipine (intraperitoneal) or combined vitamin E (oral) and nimodipine counteracted DBP-induced hippocampal apoptosis, oxidative stress, and behavioral impairments, with effects observed after 28 days of exposure.125,126 Notably, 21-day co-exposure to bisphenol-phthalate mixtures in rats triggered neurobehavioral deficits and hippocampal apoptosis, which were reversed by oral morin.127 Most treatments were administered over 3–4 weeks to mimic chronic exposure, with routes including oral gavage, intraperitoneal injection, and dietary incorporation. EDCs disrupt neurotransmission in the CNS by altering glutamate receptor expression (NMDA/AMPA) and upregulating enzymes like AChE and butyrylcholinesterase (BuChE), which impair synaptic function. Curcumin restored BPA-suppressed glutamate receptor levels in rats,25 while flavonoids such as morin and naringin (orally administered) downregulated AChE and BuChE hyperactivity induced by plasticizers, improving synaptic signaling.127,128 In vitro studies corroborate the neuroprotective potential of antioxidants in CNS cells. Pretreatment with ALA (4 h before BPA exposure) reduced oxidative damage in hippocampal cells by improving mitochondrial function and synaptic protein expression.124 Similarly, ALA mitigated BPA-induced astrocyte toxicity, reactive gliosis, and ROS generation.121 Mushroom extracts (Auricularia polytricha) and ergosterol attenuated neuroinflammation and oxidative stress in microglial and hippocampal cells exposed to BPA.123 Discussion Impact of bisphenols and phthalates on neurodevelopment and mental health: An integrative synthesis Accumulating evidence indicates that environmental EDCs, particularly bisphenols (e.g., BPA, BPS, and BPF) and phthalates (e.g., DEHP, DINP, and DBP) can influence neurodevelopment and modulate vulnerability to mental disorders when exposure occurs during critical developmental windows, including gestation, the perinatal period, and early childhood. Although disorders such as anxiety, depression, ADHD, and ASD are multifactorial and strongly shaped by genetic background, epidemiological and experimental data increasingly support a role for these compounds as environmental modifiers of risk, with effects that depend on sex, timing of exposure, and the specific molecule involved. Epidemiological evidence in humans Population-based studies consistently associate exposure to bisphenols and phthalates with alterations in key neurodevelopmental domains, including language, social behavior, learning and memory, and emotional regulation. A recurrent feature across cohorts is sexual dimorphism in exposure outcome relationships. For example, urinary metabolites of DEHP have been associated with a reduction in the Mental Development Index in girls, whereas changes in psychomotor development indices have been reported in boys. Similarly, elevated maternal urinary concentrations of phthalates and BPA during pregnancy have been linked to language deficits in offspring, with effects generally more pronounced in boys. During childhood, higher urinary levels of bisphenols (BPA, BPS, and BPF) and phthalates have been associated with reduced social competence, including increased emotional reactivity, somatic complaints, social withdrawal, and behavioral problems. Although both sexes are affected, the overall burden of altered social functioning tends to be greater in boys. When specific mental health outcomes are considered, distinct patterns emerge. For anxiety and depression, BPA shows relatively consistent associations with anxiety and depressive symptoms, with effects that depend on exposure window, age, plasticizer, and sex. Prenatal BPA has been linked to greater anxious/depressed symptoms in boys, whereas higher postnatal BPA measured in early childhood relates more often to symptoms in girls85; other cohorts report prenatal associations in girls or null childhood findings.86 Prenatal MBzP has been associated with anxiety/depression at age 3 in girls,79 yet some studies find lower anxiety scores with higher prenatal DEHP and MBzP in girls.80 Measures of the sum of DEHP metabolites have been linked to anxious/depressed symptoms in girls at later ages in some cohorts but not in earlier assessments.81 Several studies report associations between prenatal MnBP or MiBP and early-childhood anxiety or depression problems,82,83 while metabolite analyses show mixed associations across CBCL and BASC instruments.84 Finally, emerging evidence suggests that BPA replacements may not be safer, as higher serum BPS has been reported in adults with major depressive disorder compared with controls.2 For ADHD, epidemiological evidence indicates that DEHP shows the most consistent association, particularly following prenatal exposure and in children with a clinical diagnosis, while findings for DINP are mixed. Evidence for bisphenols is heterogeneous: several studies report null associations, but others link childhood exposure to BPA, BPF, and BPS with higher ADHD symptom burden at specific ages and with sex-dependent patterns. For example, no association was observed between prenatal high BPA and ADHD at ages 2 and 5,94 whereas childhood urinary BPA, BPF, and BPS at age 6 were associated with increased ADHD scores, stronger in girls.95 In cross-sectional data, higher urinary BPA in children aged 8–15 was linked to elevated ADHD symptom counts, stronger in boys.99 Maternal serum BPA was associated with ADHD-related behaviors at age 3 but not at age 4,101 and another study found no associations between childhood bisphenols measured at 2–5 years and ADHD.96 Several phthalate metabolites, including MBzP, MHPP, and MnBP, were associated with ADHD symptoms only in children with ASD and not in controls.96 In MoBa, MnBP was linked to higher odds of ADHD at age 3 in boys but not girls, and a separate MoBa analysis reported an association between DEHP and increased offspring ADHD risk.98,102 Case-control and clinical comparisons also report higher spot urine or serum concentrations of specific phthalate metabolites and BPA in ADHD-diagnosed children.97,100 In ASD, epidemiological evidence is mixed but indicates that prenatal exposure to specific phthalate metabolites and BPA may be associated with autistic-like behaviors, with effects that differ by metabolite, age at assessment, and sex. Higher gestational concentrations of MBP and MCPP have been linked to increased ASD-related behaviors in boys,87 and a separate analysis found associations of MCPP, MBP, and BPA with greater autistic-like behaviors, stronger in boys, whereas MEP was inversely associated and DEHP showed no relation.90 Other studies report null findings at age 3 but MCPP-related increases at 4–8 years,91 shifting metabolite-behavior patterns across assessments at 1.5, 3.5, and 6 years,92 and early BPA associations that do not persist at older ages.94 Biomonitoring in diagnosed cases is inconsistent: some reports show no differences in urinary or plasma phthalate/BPA levels between ASD and control groups, while others report higher serum concentrations of multiple plasticizers in ASD patients.88,89,93 Together, the associations were metabolite and age dependent with occasional sex-specific effects, and recently, it has been reported that the lower glucuronidation of phthalate metabolites in ASD patients could increase susceptibility even when circulating levels are not elevated. Experimental evidence from animal models Animal studies provide strong mechanistic support for the associations observed in humans. Prenatal or neonatal exposure to DEHP, BPA, and DBP induces persistent impairments in spatial memory, learning, social interaction, and emotional behavior, accompanied by molecular and cellular alterations in the hippocampus, amygdala, and prefrontal cortex. Mechanistic evidence indicates that plasticizer exposure during critical stages of brain development disrupts endocrine-sensitive molecular pathways in disorder-specific yet interconnected ways, providing biological plausibility for anxiety, depression, ADHD, and ASD. In affective disorders, bisphenols and phthalates reduce hippocampal serotonin availability, alter glucocorticoid receptor signaling, and upregulate stress-responsive genes such as Crh while downregulating Nr3c1, leading to chronic hyperactivation of the HPA axis and heightened vulnerability to anxiety and depressive phenotypes; these effects are further amplified by neuroinflammatory signaling through microglial release of IL-1β and TNF-α that impair synaptic plasticity and neurogenesis. In ADHD-related mechanisms, early-life exposure disrupts dopaminergic neuron development and dopamine receptor and transporter expression in cortical and midbrain circuits, alongside altered neuronal-glial fate decisions and impaired excitatory-inhibitory synaptic connectivity, resulting in hyperactivity, attentional deficits, and aberrant network maturation. For ASD, plasticizers interfere with estrogen and thyroid hormone signaling, reprogram neural stem cell differentiation, dysregulate synaptogenesis genes involved in axon guidance and social circuitry, and activate the mTOR pathway while suppressing autophagy, collectively producing impaired social behavior, repetitive actions, and altered cortical wiring. Across all three disorders, epigenetic modifications—including DNA methylation of neurodevelopmental and hormone-regulated genes—likely stabilize these molecular alterations over time, while the strong hormonal dependence of these pathways offers a mechanistic explanation for the consistent sexual dimorphism observed in both epidemiological and experimental studies. Together, these disorder-linked molecular cascades illustrate how low-dose plasticizer exposure can translate endocrine disruption into long-term neuropsychiatric vulnerability. Sex-dependent effects are evident across models, with male rodents generally displaying greater vulnerability to depressive-like behaviors, ADHD-like phenotypes, and autism-like traits following exposure to BPA, DEHP, or DBP. These findings parallel epidemiological observations in children. Moreover, studies evaluating mixtures of bisphenols and phthalates often report more pronounced neurobehavioral effects than single-compound exposures, highlighting the relevance of mixture toxicity to real-world conditions. Damage-reduction strategies and evidence of neuroprotection Mechanistic studies indicate that the neurotoxic effects of bisphenols and phthalates on oxidative balance, inflammatory signaling, apoptosis, and synaptic integrity are directly linked to the emergence of anxiety, depression, ADHD, and ASD-like phenotypes and that modulation of these pathways can effectively attenuate such behavioral outcomes. Plasticizer-induced mitochondrial dysfunction and excessive ROS activate apoptotic cascades in hippocampal and cortical neurons, while microglial-driven neuroinflammation disrupts neurogenesis and circuit maturation processes that underlie emotional dysregulation, cognitive impairment, and social deficits. Antioxidant and anti-inflammatory compounds such as curcumin, ALA, morin, and flavonoids restore redox homeostasis, suppress neuronal apoptosis, and normalize microglial activation, leading to recovery of learning, memory, and affective behaviors in exposed animals. Concurrently, these treatments reverse plasticizer-driven synaptic alterations by stabilizing glutamatergic receptor expression and inhibiting AChE and BuChE hyperactivity, thereby improving neurotransmission and network plasticity essential for attention control and emotional regulation. In vitro findings further support that preservation of mitochondrial function and reduction of reactive gliosis protect neuronal and astrocytic support systems critical for healthy brain development. Together, these mechanistic reversals demonstrate that the molecular cascades triggered by plasticizer exposure are not only central to neuropsychiatric dysfunction but are also modifiable, offering strong biological evidence that targeting oxidative, inflammatory, and synaptic pathways can mitigate plasticizer-associated mental health disturbances. Dose exposure and its implications in health and disease effects Human biomonitoring data indicate that exposure to plasticizers begins in utero and persists throughout life, with urinary BPA concentrations in pregnant women commonly around 1.30–1.46 ng/mL and phthalate metabolites such as MEP approaching 100 ng/mL during gestation in the United States. Epidemiological studies have linked these early-life exposures to anxiety, depression, ADHD, and autistic traits in a sex-dependent manner, with prenatal BPA often showing stronger associations in boys for affective symptoms and neurodevelopmental outcomes, while postnatal exposure in some cohorts appears more relevant for girls. Experimental evidence closely parallels these patterns, demonstrating that perinatal BPA at environmentally relevant low doses (10–50 μg/kg/day) and higher doses up to 10 mg/kg/day induces depressive- and anxiety-like behaviors predominantly in male rodents, alongside serotonergic disruption and heightened HPA-axis activity, whereas females frequently exhibit attenuated or compensatory molecular responses. Similarly, phthalate exposure, including DEHP at 5–200 mg/kg/day and DMEP at 50 mg/kg/day, produces ADHD-like hyperactivity and affective disturbances largely in males, with mechanistic links to thyroid hormone disruption, dopaminergic dysfunction, and altered cortical development. Although experimental doses often exceed estimated daily human intake, the chronic nature of human exposure and the non-linear dose-response characteristics of endocrine EDCs suggest that the low but persistent concentrations observed in humans are sufficient to engage comparable neurodevelopmental pathways. The concordance in dose sensitivity, developmental timing, and pronounced sexual dimorphism across human and animal studies strongly supports a biologically plausible role for plasticizers in shaping long-term mental health vulnerability. Implications for public policy The existing evidence underscores the need for population-level policies targeting pregnancy and early life, focusing on chemical class regulation, standardized labeling, and restrictions on bisphenols and phthalates in products for vulnerable populations. Key measures include avoiding regrettable substitutions, implementing biomonitoring programs, and promoting viable alternatives such as reducing plastic use, using glass, and exploring bioplastics. Global regulatory actions have been taken, including EU restrictions on bisphenols (BPA) and phthalates such as DEHP, BBP, and DBP, with similar restrictions in the US, Japan, and Korea. The EU’s REACH Annex XVII restricts DEHP, BBP, DIBP, and DnBP, requiring authorization for use. Limits have been set for plasticizers such as tributyl citrate, acetate, and DEHA in food packaging, aiming to mitigate endocrine-disrupting effects as extensively reviewed by Flora et al.134,135 Scope and limitations of the evidence Despite substantial convergence between epidemiological and experimental findings, important limitations remain. These include heterogeneity in exposure assessment (frequent reliance on spot urine samples that capture short-lived metabolites over 6–24 h, differing units, and sometimes unreported concentrations), variability in outcome measurement (clinical diagnoses versus parent-reported questionnaires, which can under- or overestimate symptom severity) and potential misclassification, residual confounding by socioeconomic and environmental factors, and a predominance of observational designs that limit causal inference. Animal studies are often male biased, and many human analyses do not stratify by sex. Apparent inconsistencies across studies likely reflect differences in exposure window, age at assessment, chemical mixtures and co-exposures, and individual susceptibility. Greater standardization of exposure metrics and outcome definitions, routine consideration of mixtures, sex-specific analyses, and longitudinal designs are needed to reduce uncertainty. Priorities for future research Progress in this field will depend on longitudinal cohorts with repeated exposure measurements across critical windows, explicit consideration of sex as a biological variable, experimental models incorporating realistic chemical mixtures, and integration of mechanistic biomarkers into human studies. In parallel, variability in detoxification pathways (e.g., glucuronidation capacity) should be examined as a determinant of susceptibility, and preventive interventions—both exposure-reduction strategies and candidate neuroprotective approaches—should be evaluated with clinical rigor. Concluding remarks (1)Evidence from both animal models and epidemiological studies consistently indicates that exposure to bisphenols and phthalates during critical developmental windows—particularly the perinatal and neonatal periods—heightens vulnerability to psychiatric conditions such as depression, anxiety, ADHD, and ASD.(2)Across many experimental paradigms, males appear to be more susceptible to the neurobehavioral consequences of plasticizer exposure.(3)Adverse neurological effects have been observed even at very low, environmentally relevant doses, reinforcing concerns about chronic, real-world exposure.(4)At the molecular level, these compounds disrupt neuroendocrine signaling pathways, promote the release of proinflammatory cytokines, and enhance oxidative stress, particularly in the hippocampus and cortex.(5)Several natural and synthetic compounds have shown the capacity to attenuate or counteract plasticizer-induced neurotoxicity by targeting the same oxidative, inflammatory, and neuroendocrine pathways altered by these EDCs. (1)Evidence from both animal models and epidemiological studies consistently indicates that exposure to bisphenols and phthalates during critical developmental windows—particularly the perinatal and neonatal periods—heightens vulnerability to psychiatric conditions such as depression, anxiety, ADHD, and ASD. )Evidence from both animal models and epidemiological studies consistently indicates that exposure to bisphenols and phthalates during critical developmental windows—particularly the perinatal and neonatal periods—heightens vulnerability to psychiatric conditions such as depression, anxiety, ADHD, and ASD. (2)Across many experimental paradigms, males appear to be more susceptible to the neurobehavioral consequences of plasticizer exposure. Across many experimental paradigms, males appear to be more susceptible to the neurobehavioral consequences of plasticizer exposure. (3)Adverse neurological effects have been observed even at very low, environmentally relevant doses, reinforcing concerns about chronic, real-world exposure. Adverse neurological effects have been observed even at very low, environmentally relevant doses, reinforcing concerns about chronic, real-world exposure. (4)At the molecular level, these compounds disrupt neuroendocrine signaling pathways, promote the release of proinflammatory cytokines, and enhance oxidative stress, particularly in the hippocampus and cortex. At the molecular level, these compounds disrupt neuroendocrine signaling pathways, promote the release of proinflammatory cytokines, and enhance oxidative stress, particularly in the hippocampus and cortex. (5)Several natural and synthetic compounds have shown the capacity to attenuate or counteract plasticizer-induced neurotoxicity by targeting the same oxidative, inflammatory, and neuroendocrine pathways altered by these EDCs. Several natural and synthetic compounds have shown the capacity to attenuate or counteract plasticizer-induced neurotoxicity by targeting the same oxidative, inflammatory, and neuroendocrine pathways altered by these EDCs. Acknowledgments This research was funded by grants from Programa de Apoyo a Proyectos de Innovación Tecnológica (PAPIIT), 10.13039/501100006087Dirección General de Asuntos del Personal Académico (DGAPA), 10.13039/501100005739Universidad Nacional Autónoma de México (UNAM): IN206826 to J.M.-M., IN225825 to K.E.N.-C., and IF200726 to C.A.G.-C. This research was also funded by a grant from 10.13039/501100003141Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) to J.M.-M. (CY001913). D.L.R.-A. (CVU 1269810), M.d.S.R.-A. (CVU 1129322), and C.A.Z.-L. (CVU 2168168) are the recipients of master’s in science SECIHTI Fellowships. D.L.R.-A., M.d.S.R.-A., and C.A.Z.-L. acknowledge the Posgrado en Ciencias Biológicas y Ciencias Bioquímicas at Universidad Nacional Autónoma de México. Author contributions Conceptualization, J.M.-M., C.A.G.-C., Y.R.-S., D.L.R.-A., C.A.Z.-L., and M.d.S.R.-A.; data curation, C.A.G.-C., M.d.S.R.-A., and C.A.Z.-L.; formal analysis, C.A.G.-C. and L.P.; funding acquisition, J.M.-M., K.E.N.-C., and C.A.G.-C.; investigation, C.A.G.-C., Y.R.-S., D.L.R.-A., M.d.S.R.-A., C.A.Z.-L., Y.D.C.-R., L.S.-G., and L.E.J.-H.; project administration, J.M.-M.; supervision, C.A.G.-C., L.P., and J.M.-M.; visualization, C.A.G.-C., M.d.S.R.-A., C.A.Z.-L., and Y.R.-S.; writing – original draft, C.A.G.-C., Y.R.-S., D.L.R.-A., M.d.S.R.-A., C.A.Z.-L., Y.D.C.-R., L.S.-G., and L.E.J.-H.; writing – review and editing, C.A.G.-C., K.E.N.-C., L.P., and J.M.-M. Declaration of interests The authors declare no competing interests.